The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy

Guo Li¹, Yuan Tian¹,²† and Wei-Guo Zhu¹,²*

¹ Guangdong Key Laboratory for Genome Stability and Human Disease Prevention, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Shenzhen University Health Science Center, Shenzhen, China, ² Shenzhen Bay Laboratory, Shenzhen, China

Genetic mutations and abnormal gene regulation are key mechanisms underlying tumorigenesis. Nucleosomes, which consist of DNA wrapped around histone cores, represent the basic units of chromatin. The fifth amino group (Nε) of histone lysine residues is a common site for post-translational modifications (PTMs), and of these, acetylation is the second most common. Histone acetylation is modulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), and is involved in the regulation of gene expression. Over the past two decades, numerous studies characterizing HDACs and HDAC inhibitors (HDACi) have provided novel and exciting insights concerning their underlying biological mechanisms and potential anti-cancer treatments. In this review, we detail the diverse structures of HDACs and their underlying biological functions, including transcriptional regulation, metabolism, angiogenesis, DNA damage response, cell cycle, apoptosis, protein degradation, immunity and other several physiological processes. We also highlight potential avenues to use HDACi as novel, precision cancer treatments.

Keywords: cancer therapy, HDAC, HDAC inhibitors, HDAC sequence, histone modification

INTRODUCTION

In the nuclei of eukaryotic cells, the entire genome of an organism is condensed into chromatin. The nucleosome is the basic unit of chromatin: it contains 147 DNA base pairs coiled around a core histone octamer, which includes histones H2A, H2B, H3 and H4 (Luger et al., 1997; Tessarz and Kouzarides, 2014). The additional linker histone H1 interacts with chromatin outside of the core octamer to regulate higher order chromatin structure (Fyodorov et al., 2018). There are two major higher order structures: heterochromatin refers to condensed chromatin, and euchromatin refers to loosely packed chromatin that is more accessible to transcriptional regulators and RNA polymerase complexes (Allfrey et al., 1964). Thus, alteration and regulation of chromatin structure impacts gene expression by making certain genes more or less available for transcription.

The epigenome is comprised of modifications to chromatin, including DNA methylation and histone modifications. For example, DNA accessibility is regulated by nucleosome sliding or post-translational modifications (PTMs), which include phosphorylation, methylation and acetylation. These covalent modifications control the structure and function of chromatin through a number of regulators. These regulators can be broadly divided into “readers” (enzymes that bind to modifications and facilitate epigenetic activities), “writers” (enzymes that establish DNA
methylation or histone modifications), and “erasers” (enzymes that remove these markers) (Taverna et al., 2007; Kutateladze, 2011; Musselman et al., 2012; Huang et al., 2014; Xu et al., 2017). As an example, acetylation occurs at the fifth NH2 (Nε) of histone lysine residues (Strahl and Allis, 2000; Jenuwein and Allis, 2001), and is read by the bromodomain-containing protein (BRD), written by histone acetyltransferases (HATs), and erased by histone deacetylases (HDACs) (Dawson and Kouzarides, 2012; Filippakopoulos and Knapp, 2014; Zaware and Zhou, 2019).

The acetylation of lysine residues (Kac) on histone tails generates positive charges, which neutralize negatively charged DNA and the unwinding of tightly coiled heterochromatin (Shogren-Knaak et al., 2006). Histone acetylation can increase the inner pore space of chromatin from 20 nm to 60–100 nm, altering spatial distance and accessibility during interphase (Gorisch et al., 2005); it also ensures sufficient space for local transcriptional events, including initiation and elongation (Wang et al., 2009). Acetylation is of particular importance because the interaction between histones and chromatin is generally very stable, and interruption of this interaction requires a high concentration of NaCl or acetate (Von Holt et al., 1989; Shechter et al., 2007). Notably, acetylation is often a necessary precursor to other modifications, such as phosphorylation, methylation and ubiquitylation (Yang and Gregoire, 2007; Yang and Seto, 2008a).

Acetylation is controlled by two antagonistic enzyme families: HATs and HDACs. HDACs are expressed by various tumors, and are involved in vital chromosomal translocation-mediated oncogenic protein fusion and carcinogenic events (Falkenberg and Johnstone, 2014; West and Johnstone, 2014). These enzymes were first revealed to remove acetyl groups from histones by Vincent Allfrey (Inoue and Fujimoto, 1969). The first HDAC that was discovered, HDAC1, was originally isolated by utilizing a microbe-derived cyclic tetrapeptide, Trapoxin, which inhibits histone deacetylation and induces cell-cycle arrest (Taunton et al., 1996). Sequence homology-dependent HDACs were subsequently identified, and shown to be involved in major biological functions such as transcription, metastasis, autophagy, cell cycle, DNA damage repair, angiogenesis, stress responses and senescence (Yang and Seto, 2008b; Li and Zhu, 2014).

Histone deacetylase inhibitors (HDACi) might be able to reverse the activation of tumor suppressor genes, and in this way inhibit the viability and malignant proliferation of tumor cells (Glozak and Seto, 2007). The efficacy of HDACi treatment has been demonstrated in numerous clinical studies. This review discusses HDACs and their inhibitors in the context of potential cancer treatments.

CLASSIFICATIONS, ENZYMATIC ACTIVITIES AND CELLULAR DISTRIBUTIONS OF HDACs

Classifications of HDACs
According to their sequence similarities with yeast HDACs, 18 human HDACs have been identified and grouped into four classes (Yang and Seto, 2008b; Seto and Yoshida, 2014). Class I HDACs include HDAC1, -2, -3, and -8 (Rundlett et al., 1996; Taunton et al., 1996; Yang et al., 1996, 1997; Emiliani et al., 1998; Buggy et al., 2000; Hu et al., 2000; Van Den Wyngaert et al., 2000). Class II HDACs are further divided into two subgroups: class IIa and class IIb. Class IIa includes HDAC4, -5, -7, and -9 and class IIb includes HDAC6 and -10 (Grozinger et al., 1999; Miska et al., 1999; Wang et al., 1999; Kao et al., 2000, 2002; Zhou et al., 2001; Fischer et al., 2002; Guardiola and Yao, 2002; Tong et al., 2002). Class III, also known as the sirtuins (SIRTs), include SIRT1-7 (Imai et al., 2000; Lin et al., 2000), and class IV contains only HDAC11 (Gao et al., 2002). SIRTs are nicotinamide adenine dinucleotide (NAD+)-dependent enzymes, while the other three classes are Zinc cation (or Zn2+ ion)-dependent HDACs. Besides the deacetylase activity, a number of diverse enzymatic activities of HDACs are presented in Table 1 and the sequence characteristics of HDACs are presented in Figure 1.

Compositions, Sequence Characteristics, and Cellular Distributions of HDACs

Class I HDACs
Of class I HDACs, HDAC1, -2, and -3 catalytic activities depend on their respective co-repressor complexes. Based on the conserved structures and dimerization domains, HDAC1 and HDAC2 are often recruited to the same co-repressor complexes, including Mi-2/nucleosome remodeling deacetylase (NuRD), repressor element-1 transcription co-repressor (RCOR1/CoREST), SWI-independent-3A (Sin3A) and mitotic deacetylase complex (MiDAC) (Hassig et al., 1997; Laherty et al., 1997; Nagy et al., 1997; Ayer, 1999; You et al., 2001; Bantscheff et al., 2011; Itoh et al., 2015; Turnbull et al., 2020). HDAC3 associates with the nuclear receptor co-repressor (NCoR) and silencing mediator for retinoid or thyroid-hormone receptors (SMRT) to form co-repressors. The NCoR/SMRT complex provides a platform for the recruitment and activation of HDAC3 in the deacetylase-activating domain (DAD) of SMRT (Wen et al., 2000; Oberoi et al., 2011; Emmett and Lazar, 2019). Inositol phosphate, an intermolecular “glue”; binds to the interface between the co-repressors and HDAC catalytic domains, improving the catalytic activity of the HDACs in NuRD and NCoR/SMRT complexes (Watson et al., 2012, 2016; Millard et al., 2013). Particularly, the HDAC8 monomer accommodates substrates with a unique flexible L1 loop in its N-terminal region, which is absent in other HDACs (Somoza et al., 2004). Therefore, this motif is likely to be conducive to the development of HDAC8-specific inhibitors (Ingham et al., 2016). Furthermore, its crystal structure indicates that dimerization occurs at the binding interface between HDAC8 and its substrate (Castaneda et al., 2017).

Class II HDACs
All Class IIa HDACs include an extended N-terminal domain that contains conserved serine (Ser) residues and other motifs for localization and function (Yang and Gregoire, 2005). Based on these Ser residues, several kinases such as
TABLE 1 | The multifaceted catalytic functions of HDACs.

| Enzymatic activities          | HDACs                      | References                                      |
|-------------------------------|----------------------------|-------------------------------------------------|
| deacetylase                   | All HDACs                  | –                                               |
| polyamine deacetylase         | HDAC10                     | Hai et al., 2017                                |
| fatty acid deacetylase        | HDAC8, HDAC11, SIRT6       | Houtkooper et al., 2012; Feldman et al., 2013; Jiang et al., 2013; Aramsangtienchai et al., 2016; Wang et al., 2016; Kutil et al., 2018 |
| (de-hexanoyl, de-octanoyl, de-octanoyl, de-dodecanoyl, de-myristoyl) |                           |                                                 |
| decrotonylase                 | HDAC1, HDAC3               | Wei et al., 2017                                |
| desuccinylase                 | SIRT5, SIRT7               | Du et al., 2011; Li et al., 2016                 |
| demalonylase                  | SIRT5                      | Du et al., 2011                                 |
| de-glutaratey                 | SIRT5, SIRT7               | Tan et al., 2014; Bao et al., 2019               |
| de-methylglutarylase          | SIRT4                      | Anderson et al., 2017                           |
| de-3-methylglutaconylase      | SIRT4                      | Anderson et al., 2017                           |
| lipoamidase                   | SIRT4                      | Mathias et al., 2014                            |
| ADP-ribosyltransferase        | SIRT5                      | Tanny et al., 1999; Haigis et al., 2006; Mao et al., 2011 |
| S-nitrosylase                 | HDAC2                      | Nott et al., 2008; Cenciioni et al., 2018       |
| SUMOylase                     | HDAC4, HDAC7               | Zhao et al., 2005; Gao et al., 2008; Yang Y. et al., 2011 |
| O-GlcNAcylation               | HDAC1, HDAC4, HDAC6, SIRT1 | Zhu et al., 2016; Ferrer et al., 2017; Kronlage et al., 2019; Tian and Qin, 2019 |
| S-glutathionylase             | SIRT1                      | Brautigam et al., 2013                          |
| benzoylase                    | SIRT2                      | Huang et al., 2018a                             |

calcium/calmodulin-dependent protein kinase (CaMK), salt-inducible kinase (SIK) and members of microtubule affinity-regulating kinase (MARK/hPar-1) phosphorylate Class IIA HDACs (Mckinsey et al., 2000, 2001; Dequiedt et al., 2006; Walkinshaw et al., 2013), which facilitates HDACs nuclear export through chromosomal region maintenance 1 protein (CRM1) [also called exportin 1 (XPO1)]- or ankyrin repeat family A protein 2 (ANKRA2)-recognized nuclear export sequence (NES) (Wang and Yang, 2001; Mckinsey et al., 2006; Xu et al., 2012). For nuclear localization, all class IIA HDACs contain nuclear localization sequence (NLS) (Zhang et al., 2002b). 14-3-3 protein inhibits the nuclear localization of these HDACs by blocking their interaction with importin α. The absence of 14-3-3 promotes HDAC4/5 nuclear localization, which also facilitates transcription repression by binding to HDAC3 (Grozinger and Schreiber, 2000; Wang et al., 2000). Of note, Class IIA HDACs contains myocyte enhancer factor 2 (MEF2) binding sites. The phosphorylated kinases-induced exported HDACs dissociate with nuclear MEF2 family proteins that are response for differentiated gene expression (Sparrow et al., 1999; Wang et al., 1999; Mckinsey et al., 2000; Walkinshaw et al., 2013). Nevertheless, Class IIA HDACs have significant weaker deacetylase activity compared to Class I. X-ray crystallography data have revealed that the catalytic pocket of histone deacetylase-like protein (HDLP) contains several key catalytic sites, such as histidine (His), aspartic acid (Asp) and tyrosine (Tyr). Class IIA HDACs have relatively low catalytic ability due to a substitution of asparagine to Asp on the Asp-His charge relay (Finnin et al., 1999). Moreover, the catalytic Tyr is conserved in other HDACs except for class IIA enzymes, where the Tyr residue is replaced by His. Substitution of His back to Tyr at 976 recovers the enzymatic activity of class IIA HDACs (Lahm et al., 2007).

Of the class IIB HDACs, HDAC6 is a microtubule-associated deacetylase that is predominantly localized in the cytoplasm. HDAC6 contains a microtubule-binding domain that promotes chemotactic cell motility (Hubbert et al., 2002; Ustinova et al., 2020); it also includes a double-tandem deacetylase domain and a serine-glutamine containing tetradecapeptide (SE14) repeats domain that is important for cytoplasmic anchoring (Bertos et al., 2004). HDAC6 undergoes nuclear export via leucine-rich motifs that are recognized by CRM1/exportin1 (Verdel et al., 2000), and contains NES at adjacent Kac sites in the N-terminal (Liu et al., 2012). HDAC6 also contains zinc-finger ubiquitin binding domains (ZnF-UBP, also called PAZ domain) that negatively regulate polyubiquitin chain turnover (Seigneurin-Berny et al., 2001; Hook et al., 2002; Boyault et al., 2006). Recently, two deacetylase domains of HDAC6 have been re-classified as catalytic domain 1 (CD1) and CD2: these domains confer differential substrate recognition (Hai and Christianson, 2016).

HDAC10 is a polyamine deacetylase that preferentially catalyzes N8-acetylsperrmidine hydrolysis to generate acetate (Hai et al., 2017; Shinsky and Christianson, 2018). It contains a leucine-rich domain, a deacetylase domain and an inactivity domain (Guardiola and Yao, 2002; Kao et al., 2002). Similar to...
class IIa HDACs, HDAC10 associates with HDAC2, HDAC3, SMRT, and NCOR2 to enhance transcriptional repression (Fischer et al., 2002; Tong et al., 2002; Jin et al., 2018).

**Class III HDACs**
A total of seven NAD$^+$-dependent class III HDACs, or SIRTs, have been identified in the cytoplasm, nucleus and mitochondria (Yao et al., 2014; Chalkiadaki and Guarente, 2015; Zhao and Zhou, 2019). SIRT1, which is distributed in the cytoplasm, mitochondria and the nucleus, has two CRM1-mediated NES and two NLS (Tanno et al., 2007); it undergoes conformational shifts in response to adenosine triphosphate (ATP), which impedes its ability to interact with substrates in the C-terminal domain (Kang et al., 2017). SIRT2 is even more widely distributed than SIRT1, being found in the plasma membrane and cytoskeleton-associated organelles in addition to the cytoplasm, nucleus and mitochondria: it contains a CRM1-dependent NES and a putative leucine-rich NES (Wilson et al., 2006). By contrast, SIRT3, SIRT4, and SIRT5 are primarily found in the mitochondria. SIRT3 has the capability to shuttle from the nucleus to the cytoplasm and mitochondria, while SIRT4 and SIRT5 are primarily found in the mitochondria.

### Domain Structure of Human HDACs

![Diagram of Domain Structure of Human HDACs](image_url)

**FIGURE 1** Domain structure of human HDACs. The fundamental structure of all deacetylases. Total number of amino acid residues and molecular weights in each HDAC were shown on the right of each protein.
mitochondria via its mitochondrial localization sequence, which is also responsible for its mitochondrial deacetylation activity (Onyango et al., 2002; Schwer et al., 2002; Lombard et al., 2007; Bao et al., 2010). Of note, these mitochondrial regulators transfer the nucleus in response to DNA damage induced by etoposide treatment or ultraviolet (UV) irradiation (Scher et al., 2007). SIRT6 has a slower catalytic rate than other active (Michishita et al., 2005; Ardestani and Liang, 2012; Jedrusik-Bode et al., 2013). SIRT6 has a slower catalytic rate than other active SIRTs on substrates because SIRT6 lacks the conserved, highly flexible NAD$^+$-binding loop, and instead contains a stable single helix (Pan et al., 2011). Finally, SIRT7, predominantly locates in the nucleolus but also exists in the cytoplasm (Nahalkova, 2015; Zhang et al., 2016) and is involved in mitochondrial function (Ryu et al., 2014; Mohrin et al., 2015). Two sequences in the N-terminal and C-terminal regions of SIRT7 permit nuclear and nucleolar localization, respectively (Kiran et al., 2013).

Class IV HDACs
HDAC11 is the exclusive member of the class IV HDACs. Recent studies have indicated that HDAC11 might predominantly be more involved in the fatty acylation of proteins compared to its weak deacetylation (Kutil et al., 2018; Cao et al., 2019).

Here, we recapitulate the detailed distributions of all 18 HDACs in Table 2.

BIOLOGICAL FUNCTIONS OF HDACs
Histone deacetylases are expressed in different tumors: class I and II HDACs are considered to be general oncoproteins that interact with substrates and regulate gene expression to promote tumorigenesis and cancer development either individually or alongside with co-repressors (Falkenberg and Johnstone, 2014; West and Johnstone, 2014). Paradoxically, SIRTs can serve as both oncoproteins and tumor suppressors (Kugel et al., 2016; Costa-Machado et al., 2018; Funato et al., 2018). We list the demonstrated knockout (KO) or knockdown models of 18 HDACs (Table 2). Because of the diverse biological function of HDACs, it is not surprising that HDACi regimens influence many cellular processes, including those that contribute to cancer progression.

Transcriptional Regulation
Transcription Modulators
Transcription factors (TFs) can either directly target DNA or undergo various PTMs to alter gene expression. In this manner, HDACs negatively regulate transcription through forming a complex with TFs or by directly regulating TF acetylation (Grunstein, 1997). For instance, the v-myc avian myelocytomatosis viral oncogene homolog (Myc) is a well-characterized proto-oncogene that promotes tumorigenesis by directly recruiting and interacting with HDACs to regulate gene expression (Liu et al., 2007; Zhang et al., 2012a). Meanwhile, Myc acetylation is also modulated by HDACs either directly or indirectly. For example, SIRT2 stabilizes N-Myc and c-Myc proteins by deacytllating and repressing neuronal precursor cell-expressed developmentally downregulated 4 (NEDD4), which mediates Myc ubiquitination and degradation (Liu et al., 2013). Consequently, the SIRT2-specific inhibitor thiomyristoyl (TM) promotes Myc ubiquitination and degradation (Jing et al., 2016). HDACi suberylanilide hydroxamic acid (SAHA) and entinostat (also called MS-275) induce Myc acetylation at K323, downregulating Myc and accompanying with tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) activation (Nebbioso et al., 2017). Therapeutic regimens that target Myc suppression using HDACi combined with DNA demethylation reagents seems to have a notable effect on non-small cell lung cancer (NSCLC) through activating immune system (Topper et al., 2017).

p53 is a well-known TSG that is crucial for mediating gene expression (Gu and Zhu, 2012; Zhu, 2017): its activity is modulated by various PTMs. HDACs and SIRTs downregulate p53 activity to promote cancer cell survival in response to oxidative stress (Juan et al., 2000; Luo et al., 2000, 2001; Vaziri et al., 2001). Specifically, HDAC1, -2, and -3 all can induce p53 deacetylation that represses p53-mediated apoptosis (Juan et al., 2000). In addition, HDAC2 modulates p53 transcriptional activity through direct p53-DNA binding (Harms and Chen, 2007). p53 binds to DNA depending on its acetylation state at K373/K382 by p300 (Gu and Roeder, 1997). HDACi deacetylase induces acetylation at K373/K382 by recruiting p300. This in turn promotes the expression of p21$^{\text{Cip1/Waf1}}$ (encoded by cyclin dependent kinase inhibitor 1A, CDKN1A) (Zhao et al., 2006). Compared to wild type p53, HDAC deficiency reduces mutant p53 (mtp53) expression both at the mRNA and protein level (Yan et al., 2013; Stojanovic et al., 2017). Besides the transcriptional regulation of mtp53, HDACs also modulate mtp53 protein stability. By inhibiting HDAC6, SAHA promotes the preferential degradation of mtp53 by downregulating heat shock protein 90 (HSP90) that suppresses p53 degradation via E3 murine double minute (MDM2) or carboxy terminus of shock protein 90 (HSP90) that suppresses p53 degradation via CHIP (Li et al., 2011). Therefore, inducing mtp53 degradation by blocking HDAC6-HSP90 might represent a novel strategy to suppress oncogenesis in the future (Alexandрова et al., 2015).

In addition to TFs, HDACs also modulate the activity of super enhancers (SEs) (Gryder et al., 2019). Enhancer RNAs (eRNAs) are short, non-coding RNA molecules that alter the transcription of target genes in cooperation with promoters (Melo et al., 2013; Hsieh et al., 2014; Danko et al., 2015; Mao et al., 2019). Trichostatin A (TSA) and SAHA reduce eRNA synthesis by inhibiting HSP90 (Greer et al., 2015). MEF2D and HDAC4/9 form a corepressor to recognize intergenic regions. HDAC4/9 depleted cells show increased H3K27ac level around the gene transcriptional start sites where show the features of active enhancers within corresponded topologically associated domains (TAD) (Di Giorgio et al., 2020). Class I-specific HDACi 4SC-202 globally increases both of H3K27ac and H3K4me3 levels around the TSS of genes, but notably decreases occupancy at proximal regions of TSS of genes such as SMAD family member 6 (SMAD6) and E2F transcription factor 8 (E2F8), which are associated with enhancer deactivation (Mishra et al., 2017). Panobinostat and
Some phenotypes observed after some manipulations of HDACs in different models.

| HDACs | Subcellular location | Knockout and knockdown models | References |
|-------|----------------------|-------------------------------|------------|
| HDAC1 | Cytoplasm; Nucleus (nucleoplasm, heterochromatin) | Accelerates tumor development in skin tumors Promotes p21-mediated cell cycle arrest in mouse embryonic fibroblasts (MEFs) | Winter et al., 2013 Zupkovitz et al., 2010 |
| HDAC2 | Cytoplasm; Nucleus (nucleoplasm, heterochromatin) | HDAC1/2 double KO (HD1/2DKO) disrupts mitotic progress, chromosome segregation and causes loss of cell viability in embryonic stem cell (ESC) HD1/2DKO represses Myc- and p53- associated tumorigenesis in lymphomas HD1/2DKO induces apoptosis in thyroid cancers HD1/2DKO causes nuclear fragmentation and mitotic catastrophe HD1/2DKO affects CD4+ T cell lineage differentiation Skeletal muscle-specific HD1/2DKO causes autophagy blockage-associated abnormal metabolism and perinatal lethality of mice HD1/2DKO downregulates T-cell receptor (TCR) signaling pathway and neoplastic transformation of immature T cells | Heideman et al., 2013 Lin et al., 2019 Haberlandt et al., 2009 Boucheron et al., 2014; Preglej et al., 2020 Montgomery et al., 2007; Moresi et al., 2012; Doyev et al., 2013 |
| HDAC3 | Plasma Membrane; Cytoskeleton (mitotic spindle); cytoplasm; Golgi apparatus; Nucleus (nucleoplasm) | Global deletion of HDAC3 causes embryonic lethality of mice; cardiac-specific deletion of HDAC3 shows only 3–4 months survival of mice accompanying with cardiac metabolic disorder and mitochondrial dysfunction Represses hepatocellular carcinoma (HCC), multiple myeloma (MM) proliferation and growth Induces genome instability, cell cycle arrest and apoptosis Disrupts DNA damage repair in HCC Affects T cell maturation Represses prostate tumorigenesis and progression Stimulates rhabdomyosarcoma differentiation and limits tumor growth in presence of tamoxifen Represses inflammatory response | Lu et al., 2018; Ho et al., 2020 Bhaskara et al., 2008; Bhaskara et al., 2010; Jiang and Hsieh, 2014 Ji et al., 2019 Hsu et al., 2015 Yan Y. et al., 2018 Phelps et al., 2016 |
| HDAC4 | Cytoskeleton (actomyosin); Cytoplasm; Nucleus (nucleoplasm) | Causes mitotic arrest and chromosome segregation Causes partial proliferation deficit in leiomyosarcomas Impairs type I IFN signaling and causes spread of DNA virus Stimulates chondrocyte differentiation Promotes cell growth of myelodyplastic syndrome (MDS) or AML Causes reduced exercise capacity, cardiac dysfunction and heart failure | Cadot et al., 2009 Di Giorgio et al., 2020 Lu Y. et al., 2019 Nishimori et al., 2019 Huang et al., 2020 Lehmann et al., 2018; Kronlage et al., 2019 |
| HDAC5 | Cytoplasm; Golgi apparatus; Nucleus (nucleoplasm) | Impairs CD8+ T-cell IFN-γ production in lung adenocarcinoma Promotes HDAC2-dependent hypertrophic stresses Stimulates chondrocyte differentiation HDAC4/5DKO confers resistance to muscle proteolysis and atrophy | Xiao et al., 2016 Eom et al., 2014 Nishimori et al., 2019 Moresi et al., 2010 |
| HDAC7 | Cytoplasm; Nucleus (nucleoplasm) | Blocks early B-cell development Affects thymocytes cell survival and thymic T cell development. Causes loss of vascular integrity and embryonic lethality Stimulates β-catenin-dependent proliferation of chondrocytes Abrogates growth of lung cancer | Azagra et al., 2016 Kasler et al., 2011 Chang et al., 2006 Bradney et al., 2015 Lei et al., 2017 |
| HDAC9 | Cytoplasm; Nucleus (nucleoplasm) | Exhibits stress-dependent cardiac hypertrophy Accelerates adipogenic differentiation Decreases CD8+ dendritic cell infiltration Decreases cell adhesion and migration, promotes apoptosis and dramatically impairs proliferation in leiomyosarcomas | Zhang et al., 2002a Chatterjee et al., 2011 Ning et al., 2020 |
| HDAC6 | Plasma membrane; Cytoskeleton (mitrotubule); Cytoskeleton; Aggresome; Endosome; Nucleus (nucleoplasm) | Induces interleukin-10 associated inflammatory response Affects immune response moderately Represses endothelial cell migration and angiogenesis Blocks autophagy flux and tumorigenesis of Myc-driven neuroblastoma or KRAS-driven colorectal cancer (CRC) and MM Confers susceptibility to RNA virus infections Impairs actin cytoskeleton-dependent cell migration | Wang B. et al., 2014 Zhang et al., 2008 Kaluz et al., 2011 Kaliszczak et al., 2018 Choi et al., 2016 Gao et al., 2007 |
| HDAC10 | Cytoplasm; Nucleus (nucleoplasm) | Promotes G2-M transition arrest in non-small cell lung cancer (NSCLC) Interrupts autophagic flux in neuroblastoma cells Activates chaperone-mediated autophagy (CMA) in HeLa cells Activates the TGF-β pathway in lung adenocarcinoma cells | Li et al., 2015 Oehme et al., 2013 Oubayashi et al., 2020 Li et al., 2020 |

(Continued)
### TABLE 2 | Continued

| HDACs | Subcellular location | Knockout and knockdown models | References |
|-------|----------------------|------------------------------|------------|
| SIRT1 | Cytoplasm; Mitochondrion; Nucleus (nuclear membrane, nucleoplasm, euchromatin, heterochromatin, nucleolus) | Impairs genome stability; embryonic lethality; Represses angiogenesis | Vaquero et al., 2007; Wang et al., 2008; Potente et al., 2007; Dioum et al., 2009; Lim et al., 2010 |
|       |                     | Impairs nicotinamide mononucleotide (NMN)-induced amelioration of liver fibrosis and NMN-dependent telomere integrity in premature aging mice | Amano et al., 2019 |
|       |                     | Causes methionine restriction-induced lethality in mouse ESC | Tang S. et al., 2017 |
|       |                     | Impairs myeloid-derived suppressor cells (MDSC) differentiation by disturbing glycolytic pathway | Liu et al., 2014 |
|       |                     | Impairs various DNA repair | Cohen et al., 2004; Yuan et al., 2007; Ming et al., 2010; Meng et al., 2020 |
|       |                     | Inhibits autophagy in MEFs | Lee et al., 2008 |
|       |                     | Causes differentiation defects of mice ESC | Tang et al., 2014 |
|       |                     | Suppresses angiogenesis in CRC | Hu et al., 2018 |
|       |                     | Inhibits glycosylation and tumor growth in breast cancer | Park et al., 2016 |
|       |                     | Increases migration and invasion and decreases sensitivity of oxidative stress upon radiation | Nguyen et al., 2014 |
|       |                     | Disturbs type I IFN signaling gene transcription and inhibits CDK9-associated proliferative signaling | Kosciuczuk et al., 2019 |
| SIRT2 | Plasma membrane; Cytoskeleton (centriole, centrosome, microtubule, meiotic spindle, mitotic spindle); Mitochondrion; Nucleus (nucleoplasm, chromosome, telomeric region) | Decreases breast cancer cell viability; Causes genomic instability and chromosomal aberration in skin squamous cell carcinoma | Jing et al., 2016; Serrano et al., 2013 |
|       |                     | Promotes NHEJ and HR repair under irradiation | Nguyen et al., 2019 |
|       |                     | Suppresses angiogenesis in CRC | Hu et al., 2018 |
|       |                     | Inhibits glycosylation and tumor growth in breast cancer | Park et al., 2016 |
|       |                     | Increases migration and invasion and decreases sensitivity of oxidative stress upon radiation | Nguyen et al., 2014 |
|       |                     | Disturbs type I IFN signaling gene transcription and inhibits CDK9-associated proliferative signaling | Kosciuczuk et al., 2019 |
| SIRT3 | Cytoplasm; Mitochondrion and mitochondrial matrix; Nucleus (nucleoplasm) | Inhibits SHMT2-involved serine disorder in CRC proliferation | Wei et al., 2018 |
|       |                     | Augments ROS generation and HIF-1α-involved glycolysis in breast cancer | Finley et al., 2011 |
|       |                     | Reduces abnormal mitochondrial physiology, oxidative stress and genomic instability | Kim et al., 2010 |
|       |                     | Reverses ROS production in GVHD | Toubai et al., 2018 |
|       |                     | Promotes colon sensitivity to inflammation and tumorigenesis of CRC | Zhang et al., 2018 |
|       |                     | Inhibits Complex I and Complex II activity of the electron transport chain; reduces mitochondrial membrane potential and impairs mitochondrial homeostasis | Ahn et al., 2008; Cimen et al., 2010; Yang et al., 2016 |
|       |                     | Enhances glycometabolism-associated proliferation of cholangiocarcinoma | Xu et al., 2019 |
|       |                     | Promotes ROS production, glycolysis, cell transformation and tumorigenesis of breast cancer | Zou et al., 2017 |
|       |                     | Induces metabolic disorder, autophagy and cell death in diffuse large B-cell lymphoma (DLBCL) | Li M. et al., 2019 |
| SIRT4 | Mitochondrion (mitochondrial inner membrane, mitochondrial matrix) | Uregulates amino acid-stimulated insulin secretion in insulinoma cells or other tissues | Haigis et al., 2006; Anderson et al., 2017 |
|       |                     | Suppresses anabolic metabolism, autophagy and cell proliferation | Shaw et al., 2020 |
|       |                     | Accelerates lymphomagenesis of Myc-induced Burkitt lymphoma and promotes glutamine metabolism | Jeong et al., 2014 |
|       |                     | Attenuates hepatic steatosis | Guo et al., 2016 |
|       |                     | Increases glutamine-dependent proliferation, stress-induced genomic instability in lung cancer | Jeong et al., 2013 |
| SIRT5 | Cytoplasm; Mitochondrion; Nucleus | Suppresses glutamine metabolism-associated tumor proliferation | Greene et al., 2019 |
|       |                     | Downregulates SHMT2-involved serine metabolism and delays tumor cell growth | Yang et al., 2018 |
|       |                     | Increases oxidative DNA damage | Chen et al., 2018 |
|       |                     | Decreases NADPH production; Increases ROS production and susceptibility to oxidative stress | Zhou et al., 2016 |
|       |                     | Disturbs BrafV600E-mediated cutaneous melanoma formation and growth | Moon et al., 2019 |
TABLE 2 | Continued

| HDACs | Subcellular location | Knockout and knockdown models | References |
|-------|----------------------|-------------------------------|------------|
| SIRT6 | Cytoplasm; Nucleus (nucleoplasm, nuclear telomeric heterochromatin, nucleolus) | Decreases ATP production and activates AMP-activated protein kinase (AMPK) to attenuate cardiac hypertrophy of mice; heart-specific SIRT5 KO induces oxidative stress and cardiac hypertrophy | Hershberger et al., 2018; Zhang et al., 2019 |
| | | Enhances aerobic glycolysis and MYC-driven tumor growth in colorectal cancer and pancreatic cancer | Sebastian et al., 2012 |
| | | Induces KRAS- and Lin28b-driven tumorigenesis of pancreatic ductal adenocarcinoma (PDAC) | Kugel et al., 2016 |
| | | Promotes FoxO1-dependent gluconeogenesis in CRC | Zhang et al., 2019 |
| | | Enhances aerobic glycolysis and MYC-driven tumor growth in colorectal cancer and pancreatic cancer | Zhong et al., 2010 |
| | | Enhances aerobic glycolysis and MYC-driven tumor growth in colorectal cancer and pancreatic cancer | Naiman et al., 2019 |
| | | Induces KRAS- and Lin28b-driven tumorigenesis of pancreatic ductal adenocarcinoma (PDAC) | Marquardt et al., 2013 |
| | | Promotes FoxO1-dependent gluconeogenesis in CRC | Ming et al., 2014 |
| | | Senses the DDR | Onn et al., 2020 |
| | | Reduces the DDR | Simon et al., 2019 |
| | | Upregulates HIF-1α and HIF-2α transcriptional activity | Hubbi et al., 2013 |
| | | Activates TGF-β | Tang X. et al., 2017 |
| | | Increases replication stress and impairs NHEJ repair | Vazquez et al., 2016 |
| | | Represses cell cycle arrest | Lu Y. et al., 2020 |
| | | Upregulates cGAS-STING pathway | Bi et al., 2020 |
| | | Causes LINE-1-associated genome instability and compromised viability | Vazquez et al., 2019 |
| | | Impairs Sirt1-PPARγ-dependent adipogenesis and adipocyte differentiation | Fang et al., 2017 |
| | | Inhibits the proliferation and invasion of thyroid cancer | Li H. et al., 2019 |
| SIRT7 | Cytoplasm; Nucleus (nucleoplasm, heterochromatin, nucleolus) | Upregulates HIF-1α and HIF-2α transcriptional activity | Hubbi et al., 2013 |
| | | Activates TGF-β | Tang X. et al., 2017 |
| | | Increases replication stress and impairs NHEJ repair | Vazquez et al., 2016 |
| | | Represses cell cycle arrest | Lu Y. et al., 2020 |
| | | Causes LINE-1-associated genome instability and compromised viability | Vazquez et al., 2019 |
| | | Impairs Sirt1-PPARγ-dependent adipogenesis and adipocyte differentiation | Fang et al., 2017 |
| | | Inhibits the proliferation and invasion of thyroid cancer | Li H. et al., 2019 |
| | | Senses the DDR | Onn et al., 2020 |
| | | Upregulates the IFN pathway | Simon et al., 2019 |
| | | Impairs differentiation in mESC and human embryoid body (hEB) | Etchegaray et al., 2015 |
| HDAC11 | Plasma membrane; Cytoplasm; Nucleus (nucleoplasm) | Enhances type I IFN signaling | Cao et al., 2019 |
| | | Enhances proinflammatory cytokine production, proliferation of T cells and GVHD | Woods et al., 2017 |
| | | Confers a metabolic homeostasis disorder | Bagchi et al., 2018; Sun et al., 2018 |
| | | Suppresses Jak2-driven proliferation and survival of myeloproliferative neoplasm (MPN) | Yue et al., 2020 |
| | | Suppresses lymph node metastases in breast cancer | Leslie et al., 2019 |

romidepsin alter the acetylation status of H3K27 by disrupting the SE topology in paired box 8 (PAX8) (Shi et al., 2019). Largazole (a cyclic peptides similar to depsipeptide) preferentially disturbs SE-driven transcripts that are frequently associated with oncogenic activities (Sanchez et al., 2018).

Transcriptional Activation

Although HDACs generally function as gene silencers, they can also activate transcription (Kurdistani et al., 2002; Wang et al., 2002). Besides the regulation of enhancers, a potential mechanism underlying this role includes the modulation of RNA polymerase II (RNAP2) by HDACs. HDACs participate in the crosstalk between RNAP2 C-terminal domain acetylation and phosphorylation (Wang et al., 2009; Blank et al., 2017; Ali et al., 2019). SIRT6 recruits and mono-ADP-ribosylates switch/sucrose non-fermenting (SWI/SNF) related, matrix associated, actin dependent regulator of chromatin subfamily c member 2 (SMARCC2/BAF170) to form active chromatin at the enhancer of heme oxygenase-1, which subsequently recruits RNAP2 (Rezazadeh et al., 2019). SIRT6 can also bind p53 to effectively recruit RNAP2 to local promoters (Li et al., 2018). SIRT6 deficiency mediates the activation of cyclin-dependent kinase 9 (CDK9) that can phosphorylate negative elongation factor (NELF) and mediate NELF release from RNAP2, facilitating the enrichment of TFs and RNAP2-related elongation factors to promote elongation of specific gene sets (Etchegaray et al., 2019). Consistently, TSA and SAHA disturb RNAP2-mediated transcriptional elongation by promoting the association between RNAP2 and NELF (Greer et al., 2015). Moreover, high doses of largazole can cause RNAP2-mediated transcriptional pausing and cell death (Sanchez et al., 2018).

DNA Methylation and Deacetylation

DNA methylation and histone modification modulate transcription, either alone or cooperatively, by altering chromatin status. HDACs and their complexes are recruited to hyper-methylated DNA through methyl-CpG binding domain containing (MBD) protein (MeCP), which has transcriptional repression roles (Jones et al., 1998; Nan et al., 1998; Ng et al., 1999; Zhang et al., 1999; Zhu et al., 2003). To maintain DNA methylation, DNA (cytosine-5-)methyltransferase 1 (DNMT1) binds to HDAC1 and HDAC2 to establish heritable
transcriptional silencing (Robertson et al., 2000; Rountree et al., 2000). A number of major breakthroughs involving combinations of HDACi and DNA demethylation reagents [DNA methyltransferase inhibitors (DNMTi)] have occurred in the past two decades (Cameron et al., 1999; Zhu et al., 2001b; Topper et al., 2017). The rationale underlying combined DNMTi and HDACi therapy lies in their synergistic effects on compacted chromatin. Dense methylation of CpG islands (CGI) is responsible for silencing genes, which can be reactivated by HDACi. In this scenario, TSA loosens the structure of chromatin and induces the expression of previously silenced genes in the presence of DNMTi (Jones et al., 1998, 2016; Cameron et al., 1999). The combination of 5-aza-2’-deoxycytidine (5-Aza-CdR, decitabine, Dacogen, Otsuka) and either depsipeptide or TSA induces the expression of p21^Cip/Waf1, p15 (CDKN2B/INK4B), p16 (CDKN2A/INK4B), and p19 (CDKN2D/INK4D) (Cameron et al., 1999; Zhu et al., 2001a). Depsipeptide and acipidin induce demethylation and re-activate silenced genes such as p16, GATA binding protein 4 (GATA4) and sal-like protein 3 (SALL3) by inhibiting DNMT1 binding to these gene promoters (Wu et al., 2008). In terms of the direct anti-tumor effects, DNMTi in combination with HDACi can provoke a durable, powerful clinical response in patients (Jones et al., 2016). Several combinational therapies present in regimen of reversing tumor immune evasion in NSCLC. Azacytidine plus ITF-2357 (givinostat) seems to be the most efficient strategy that augments antigen presentation machinery and interferon α/β (IFNα/β)-related immune gene activation, and mainly focuses on suppression of Myc-driven tumorigenesis (Topper et al., 2017). With their broad range of physiological functions in various tissues, the combined effects of HDACi and DMNTi hold substantial therapeutic promise going forward.

**Synergetic Regulation of HDACs and Other Histone Modifiers**

In addition to DNA methylation, HDACs also cooperate with other epigenetic modifiers. For example, lysine-specific demethylase 1 [LSD1, lysine demethylase 1A (KDM1A)] is responsible for removing mono- or di-methylation of H3K4, and represses transcription via the CoREST-HDAC complexes (Humphrey et al., 2001; Lee et al., 2005; Shi et al., 2005). A dual inhibitor of HDAC and LSD1, corin, has been developed to suppress CoREST-HDAC complexes and to coordinately increase H3K4me1, H3K27ac and H3K27me3 (Kalim et al., 2018; Anastas et al., 2019). KDM2B induces H3K79 demethylation and transcriptional repression in a SIRT1-dependent manner (Kang et al., 2018). KDM4A modulates gene repression through a physiological interaction with the NCoR-HDAC3 complex (Zhang et al., 2005). KDM5A directly associates with HDAC complexes to regulate H3K4me2/3 (Nishibuchi et al., 2014). The H3K36me2 demethylase KDM8 increases H3/H4 acetylation and Cyclin A1 transcriptional activation by impeding HDAC1 recruitment (Hsia et al., 2010).

Regarding histone lysine methyltransferases, HDAC3 modulates the H3K9ac/H3K9me3 transition in a suppressor of variegation 3-9 homolog 1 (SUV39H1, also called KMT1A)-dependent manner during the DNA damage response (DDR) (Ji et al., 2019). SIRT1 regulates H3K9 methylation by deacetylating K266 in the Su(var)3-9, enhancer-of-zeste and trithorax (SET) domain of SUV39H1, thus increasing its activity during heterochromatin formation (Shankaranarayana et al., 2003; Vaquero et al., 2007). While SIRT6 induces the monoubiquitination of histones (H3, H4) in the pre-SET domain of SUV39H1, removing SUV39H1 from IκBα negatively regulates the nuclear factor-kappaB (NF-κB) pathway (Santos-Barriopedro et al., 2018). Depsipeptide decreases H3K9me2/3 expression by reducing the expression of SUV39H1 and G9A (also called KMT1C) (Wu et al., 2008). SIRT2 binds and deacetylates PR-Set7/SET8/KMT5A at K90, and increases the H4K20me1 level (Serrano et al., 2013). HDACs also interact with polycomb-group (PcG) proteins to reset chromatin remodeling and transcriptional repression (Van Der Vlag and Otte, 1999; Kuzmichev et al., 2005; Zhang et al., 2012b; Fukumoto et al., 2018). SIRT1 interacts with Set7/9 (also called KMT7), with several sites being methylated by Set7/9. In response to DNA damage, SIRT1-p53 binding is significantly enhanced in the presence of Set7/9 and this binding coincide with increased p53 acetylation at K382 (Liu et al., 2011).

The BRD family proteins are readers of Kac (Dhalluin et al., 1999; Fujisawa and Filippakopoulos, 2017). Class I HDACi 4SC-202, mocetinostat and entinostat induce increase of hundreds of gene expression, which are mostly enriched upon BRD4- and MYC-targeted TSS-proximal regions. p21 is activated by 4SC-202 to inhibit cell proliferation (Mishra et al., 2017). Similarly, JQ1 cooperates with SAHA to inhibit the growth of pancreatic ductal adenocarcinoma (PDAC) by upregulating p57 (CDKN1C) that usually blocked by Myc (Mazur et al., 2015). Besides, HDACs also interact with protein arginine methyltransferases (PRMTs) to regulate gene transcription (Qi et al., 2018; Yan W. W. et al., 2018). These findings all highlight the competition among the “readers”, “writers” and “erasers” at acetylated histones and non-histones, and may provide additional, novel and combination epigenetic approaches for cancer therapy in the future (Figure 2).

**Metabolism**

Various kinases and metabolic pathways form a complex network with epigenetic co-repressors to dynamically regulate metabolic flux and enzyme activity; aberrations in these processes can result in tumorigenesis and cancer progression. Metabolism can affect protein acetylation by altering the concentration of NAD^+ and acetyl-CoA. In turn, HDACs also mediate metabolic reprogramming in cancer cells (Verdin and Ott, 2015).

Cancer cells are often characterized by their strong glycolytic activity, with aerobic glycolytic activity being preferred for tumor energy metabolism (Weinhouse, 1956). Increased glycolysis is associated with the abnormal regulation of glycolytic enzymes and other glucose metabolism pathways. Class II HDACs induce trans-repression of gluconeogenic enzymes from the cytoplasm to the nucleus in an HDAC3-dependent manner, and mediate the deacetylation and activation of the forkhead box class O (FoxO) family in the nucleus (Mihaylova et al., 2011). SIRT2 deacetylated isocitrate dehydrogenase 1 (IDH1) at K224 and promotes IDH1 enzymatic activity. The hypoacetylated IDH1 converts isocitrate into α-ketoglutarate in the tricarboxylic acid (TCA) cycle to inhibit liver metastases of colorectal...
cancer (CRC) (Wang B. et al., 2020). Pyruvate kinase (PKM2) promotes tumorigenesis by regulating oncogene expression and proliferation pathway activation in HDAC3-dependent way (Yang W. et al., 2011; Yang et al., 2012). SIRT6 can directly interact with and deacetylate PKM2, resulting in its nuclear export via exportin 4 and suppression of PKM2-related oncogenic functions (Bhardwaj and Das, 2016). Conversely, SIRT3 and SIRT6 also act as tumor suppressors, restricting...
aerobic glycolysis in cancer cells through destabilization of hypoxia inducible factor 1 subunit alpha (HIF-1α) and inhibition of glycolytic kinases, respectively (Finley et al., 2011; Sebastian et al., 2012). p35 directly binds and activates SIRT6 to regulate gluconeogenesis by mediating the nuclear exclusion and deacetylation of FoxO1 (Zhang et al., 2014).

The fatty acylation of proteins has a vital role in membrane synthesis, vesicle transport, protein-membrane interaction, cell signaling and localization (Resh, 2006). HDACs regulate fatty acylation during cancer progression. For example, HDAC8 performs lysine de-fatty-acylation functions. The HDAC8-selective inhibitor PCI-34051 also increases overall fatty acylation levels in Jurkat cells (Aramsangtienchai et al., 2016). HDAC11 has a relatively low effect on acetyl groups, but efficiently catalyzes dodecanoylated and myristoylated peptides (Kutil et al., 2018). Compared with acetyl peptides, some HDACs have higher catalytic efficiency on acyl groups (Houtkooper et al., 2012; Jiang et al., 2013; Aramsangtienchai et al., 2018). Compared with acetyl peptides, some HDACs have higher catalytic efficiency on acyl groups (Houtkooper et al., 2012; Jiang et al., 2013; Aramsangtienchai et al., 2016; Wang et al., 2016; Kutil et al., 2018) (see Table 1).

HDAC11 efficiently removes acyl groups on the surface of serine hydroxymethyltransferase 2α (SHMT2α), causing SHMT2α disassociation from the late endosome/lysosome. This effect leads to type I interferon receptor chain 1 (IFNαR1) polyubiquitylation and degradation, as well as downregulation of IFN signaling (Cao et al., 2019). HDAC11-specific inhibitors, such as elevenostat, FT895, and SIS17, might represent promising future treatments that target lipid metabolic dysregulation in cancers (Martin et al., 2018; Kutil et al., 2019; Son et al., 2019). SIRT3 has a role in mitochondrial fatty-acid β-oxidation by regulating long-chain acyl-CoA dehydrogenase (LCAD) (Hirschey et al., 2010). SIRT6 is indispensable for hepatic β-oxidation by deacetylating the peroxisome proliferator-activated receptor α (PPARα) coactivator nuclear receptor coactivator 2 (NCOA2) at K780 (Naiman et al., 2019). Following palmitic acid treatment, SIRT6 interacts with p53 to regulate de novo cardiolipin biosynthesis and maintain lipid homeostasis (Li et al., 2018).

Amino acids are also involved in tumorigenesis. SIRT3 deletion suppresses glutamate dehydrogenase (GDH/GLUD), which impairs glutamine flux to the TCA cycle and causes reduction of acetyl-CoA pools (Li M. et al., 2019). SIRT4 is a lipoamide deacetylase that diminishes the activity of the pyruvate dehydrogenase complex (PDH) by hydrolyzing the lipoamide cofactor dihydrolipoamide dehydrogenase transferase (DLAT) (Mathias et al., 2014). Furthermore, SIRT4 represses GDH activity through its ADP-ribosyltransferase function. SIRT4 deficiency activates GDH, stimulating amino acid-mediated insulin secretion in insulinoma cells (Haigis et al., 2006). SIRT4 also mediates other PTMs, including methylglutarylation, hydroxymethylglutarylation and 3-methylglutaconylation, and intermediates of these PTMs contribute to leucine oxidation. Indeed, SIRT4-KO induces leucine disordered metabolism and leads to glucose intolerance and insulin resistance (Anderson et al., 2017). Meanwhile, elevated SIRT5 expression in breast cancer mediates glutaminase desuccinylation and protects glutaminase from ubiquitin-mediated degradation; this effect has been associated with a poor prognosis in breast cancers (Greene et al., 2019). SIRT3 and SIRT5 also mediate desuccinylation and deacetylation of SHMT2, respectively, suggesting that suppression of serine catabolism might represent a novel strategy to restrain tumor growth (Wei et al., 2018; Yang et al., 2018).

**Hypoxia and Angiogenesis**

Activated HIFs (HIF-1α, HIF-2α, HIF-3α, and HIF-1β) have vital roles in adaptive responses, with HIF-1α and HIF-2α in particular being associated with tumorigenesis and angiogenesis in response to hypoxia (Gonzalez et al., 2018). Notably, SAHA specifically induces the accumulation of HIF-2α rather than HIF-1α in soft tissue sarcomas (Nakazawa et al., 2016). HIF-1α is ubiquitinated by von Hippel-Lindau (VHL) or by binding to p53-MDM2, inducing proteasomal dependent degradation (Vriend and Reiter, 2016; Gonzalez et al., 2018). HDAC1 downregulates p53 and VHL expression, and stimulates HIF-1α-dependent angiogenesis. TSA inhibits this process by blocking HIF-1α and the vascular endothelial growth factor (VEGF) receptor (Kim et al., 2001). Besides, HDAC4 and HDAC6 directly bind to HIF-1α. HDACi LAQ824, valproic acid (VPA) and trapoxin induce dose-dependent HIF-1α depletion in an VHL-independent manner (Qian et al., 2006). The class IIa-selective HDACi TMP195 effectively establishes an anti-tumor microenvironment and induces normalization of tumor vasculature in breast cancers by eliciting recruitment and differentiation of macrophages. TMP195 in combination with chemotherapeutic regimens such as carboplatin or paclitaxel can significantly reduce breast cancer burden (Guerriero et al., 2017).

As for SIRTs, they continuously perform an inhibitory role to HIF-1α-relevant transcriptional and metabolic regulation. During hypoxia, SIRT1 activity is inhibited due to reduced NAD+ levels, which leads to the acetylation and activation of HIF-1α and HIF-2α. SIRT1 negatively regulates angiogenesis by deacetylating FoxO1 (Potente et al., 2007; Dioum et al., 2009; Lim et al., 2010). In human breast cancers, a SIRT3 deficiency can stabilize HIF-1α (Finley et al., 2011). Both SIRT6 and SIRT7 can negatively modulate the expression and activity of HIF-1α and HIF-2α (Zhong et al., 2010; Hubbi et al., 2013).

**Redox and Oxidative Stress**

Histone deacetylase inhibitors treatment is often accompanied by oxidative stress related DNA damage that is primarily caused by the generation of reactive oxygen species (ROS) (Xu et al., 2006). In mammalian cells, two redox systems respond to oxidative stress: the thioredoxin (Trx) system and the glutathione-glutaredoxin (Grx) system. In response to nitric oxide (NO), HDAC2 is S-nitrosylated at Cys 262 and Cys 274, which induces chromatin remodeling to promote gene expression (Nott et al., 2008). A pair of redox-sensitive cysteine residues (Cys-667/Cys-669) in HDAC3 are involved in oxidative stress via the formation of intramolecular disulfide bonds (Ago et al., 2008). Compared with normal cells, tumor cells are enriched with the antioxidant Trx reductase (TrxR), which might represent a novel therapeutic target (Lu and Holmgren, 2014; West and Johnstone, 2014). Desipramine causes robust DNA damage and apoptosis by inducing ROS generation, primarily through the suppression of TrxR (Wang et al., 2012). HDAC5 represses mitochondrial ROS generation, and depletion of HDAC5 provokes nuclear
factor, erythroid 2 like 2 (NRF2)-associated transcription (Hu et al., 2019). The DNA and RNA binding protein Y-box binding protein 1 (YB-1) binds to NRF2 in response to oxidative stress. Entinostat induces YB-1 acetylation and blocks its binding to NRF2, reducing NRF2 synthesis and increasing ROS levels in sarcoma cells (El-Naggar et al., 2019).

Sirtuins primarily serve as antioxidants in redox signaling. SIRT1, -2, and -3 all prevent oxidative stress by inducing or modulating manganese superoxide dismutase (MnSOD) (Brunet et al., 2004; Wang et al., 2007). Glucose-6-phosphate dehydrogenase (G6PD) is key enzyme of the pentose phosphate pathway (PPP) that regulates nicotinamide adenine dinucleotide (NADPH) levels. NADPH maintains glutathione (GSH) at a reduced state, which serves as an antioxidant to prevent ROS generation (Chen et al., 2019). In glutathione (GSH) at a reduced state, which serves as an antioxidant to prevent ROS generation (Chen et al., 2019). In response to oxidative stress, SIRT2 and SIRT3 promote NADPH generation by deacetylating and activating G6PD and IDH2 in the PPP or in the TCA cycle, respectively. The PPP also produces ribose-5-P, which synthesizes nucleotides and generates NADH, which in turn supports SIRTs activity (Schlicker et al., 2008; Wang Y. P. et al., 2014). SIRT3 also activates NADH quinone oxidoreductase (Complex I) and succinate dehydrogenases (Complex II) in the electron transport chain (Ahn et al., 2008; Cimen et al., 2010). Furthermore, in the mitochondrial intermembrane space, SIRT5 deacetylates cytochrome c (Schlicker et al., 2008). SIRT5 is also present in peroxisomes, where it desuccinylates and inhibits peroxisomal acyl-CoA oxidase 1 (ACOX1). A SIRT5 deficiency in hepatocellular carcinoma (HCC) increases oxidative DNA damage by elevating ACOX1-mediated H2O2 production (Chen et al., 2018). By contrast, SIRTs also inhibit antioxidation; for example, SIRT2 deacetylates and suppresses peroxiredoxin (an antioxidant) in breast cancer cells (Fiskus et al., 2016; Figure 3).

DNA Damage Response

The DDR is a vitally important regulatory mechanism that protects genomic DNA from damage induced by various stimuli (Jackson and Bartek, 2009). Different levels of DNA damage are inevitably caused by UV radiation and DNA adducts, which are produced by ROS and reactive nitrogen species (RNS), as well as exposure to chemical agents (Barker et al., 2015; Roos et al., 2016; Pouget et al., 2018; Guo et al., 2020). DNA double-strand breaks (DSBs) are the most severe form of DNA damage and are repaired via one of two pathways: homologous recombination (HR) or non-homologous end-joining (NHEJ) (Scully et al., 2019). Deacetylation of H3K56 and H4K16 by HDAC1/2 are involved in mediating dynamic chromatin regulation in response to NHEJ (Miller et al., 2010). Although H4K16 acetylation attenuates binding of p53 binding protein 1 (53BP1) to H4K20me2, euchromatic histone lysine methyltransferase 1 (EHMT1, also called GLP or KMT1D)-catalyzed H4K16 monomethylation could significantly enhance this binding (Lu X. et al., 2019). Meanwhile, SIRT1 redistributes to DSB foci to promote HR during oxidative stress (Oberdoerffer et al., 2008). NuRD complex subunit, chromodomain-helicase-DNA-binding protein (CHD4), was recently discovered to be recruited by SIRT6 to replace heterochromatin 1 (HP1) at H3K9me3 to ultimately promote chromatin relaxation through HR (Hou et al., 2020). SIRT6 also mono-ADP-ribosylates and displaces KDM2A (also called JmjC domain-containing histone demethylase 1A, JHDM1A) from chromatin, which leads to HP1α-dependent H3K9me3 deposition at DSBs and transient transcriptional repression, accompanying with the recruitment of NHEJ factors (Rezazadeh et al., 2020).

The DDR is controlled by three related kinases: ataxia telangiectasia mutated (ATM), ataxia telangiectasia mutated and Rad3 related (ATR), and DNA-dependent protein kinase catalytic subunits (DNA-PKcs) (Blackford and Jackson, 2017). Once a DSB occurs, the MRE11-RAD50-NBS1 (MRN) complex and the Ku family are rapidly recruited to DSB sites. As the sensor, ATM is recruited to DSB sites by the MRN complex (Blackford and Jackson, 2017). The interplay between HDAC1 and ATM increases chromatin condensation to prevent radio-sensitivity in response to ionizing radiation (Kim et al., 1999). SIRT1 binds to deleted in breast cancer 1 (DBC1), which induces p53 activation (Kim et al., 2008; Zhao et al., 2008). ATM also mediates DBC1 phosphorylation at threonine (Thr) 454 which contributes to DBC1-SIRT1 interactions during DNA damage (Yuan J. et al., 2012). Moreover, SIRT1 deacetylates and maintains the hypoaecetylation of Nijmegen breakage syndrome protein 1 (NBS1), which is necessary for the ionizing radiation-induced phosphorylation of NBS1 and subsequent MRN complex recruitment to DSB sites (Yuan et al., 2007). SIRT7 directly binds and deacetylates ATM, which is prerequisite for ATM dephosphorylation and inactivation in the final stage of DNA repair (Tang et al., 2019). Panobinostat-induced downregulation of meiotic recombination 11 homolog (MRE11) enhances radiosensitization of bladder cancer cells by promoting MRE11 ubiquitination that relies on the upregulated E3 inhibitor of apoptosis protein 2 (cIAP2) (Nicholson et al., 2017).

ATR and its downstream kinase CHK1 are also involved in the response to DNA replication stress. SAHA slows down replication forks by restricting the ATR pathway (Conti et al., 2010). Following the conserved mechanism in yeast, VPA disrupts the formation of single-strand-DNA-RFA nucleofilaments and the activation of the Mec1 (ATR in human) and Rad53 (CHK2 in human) by suppressing the recruitment of replication factor A protein 1 (RFA1, replication protein A (RPA) in human) and DNA damage checkpoint protein Ddc2/LCD1 (ATR interacting protein (ATRIP) in human) to DNA damage sites (Robert et al., 2011). Entinostat represses checkpoint signaling during replication stress. Mechanically, HDACI/2 suppress the cell cycle kinases WEEl and CDK1 and induce the dephosphorylation of ATM and CHK2 by suppressing the expression of PP2A subunit. Entinostat also induces the incorrect incorporation of NTPs and metabolites during the induction of checkpoint kinase inactivation, which can result in mitosis catastrophe (Goder et al., 2018). Therefore, CHK inhibitors might be designed to prevent this event from occurring. Indeed, CHK1 inhibitor treatment combined with HDACi induces cell death via extensive mitotic disruption in a range of solid tumors (Lee et al., 2011).

DNA-PKcs is another sensor that is recruited to DSBs by Ku-bound DSB ends (Blackford and Jackson, 2017). Under
conditions of fasting-induced oxidative stress, SIRTs act as protective factors in the DDR. Specifically, SIRT1 deacetylates Ku70, resulting in Ku70-Bcl-2 associated protein X (BAX) disassociation and the transport of BAX away from the mitochondria, leading to stress-induced resistance to apoptosis (Cohen et al., 2004). SIRT3 also physically interacts with and deacetylates Ku70 to impede BAX translocation to the mitochondria (Sundaresan et al., 2008).

SIRTs are highly important for DNA damage repair and genome stability (Tian et al., 2019; Ng and Huen, 2020). Recent data have shown that SIRT6 is a novel sensor for initiating the DDR (Onn et al., 2020). Deacetylated SIRT6 at K33 by SIRT1 results in SIRT6 polymerization and deposition at γH2AX foci. Moreover, a SIRT6 K33R hypoacetylation mimic can rescue DNA repair defects in SIRT1-deficient cancer cells (Meng et al., 2020). SIRT7 is also associated with NHEJ, as a Sirt7 deficiency impairs the recruitment of 53BP1 to DSB sites and inhibits NHEJ efficiency (Vazquez et al., 2016). SIRT7 also deacetylates ATM to mediate ATM inactivation in the final stage of DNA damage repair (Tang et al., 2019). SIRT7 acts as a de glutarylase to regulate H4K91 glutarylation (H4K91glu). This process is closely associated with chromatin remodeling in response to DNA damage (Bao et al., 2019). Treatment with 5-Fluorouracil (5-FU) induces SIRT7 degradation in the Tat-binding protein 1 (TBP1)-mediated proteasome-dependent pathway, increasing cell radiosensitivity in combination therapy (Tang M. et al., 2017).

Poly ADP-ribose polymerases (PARPs) are central to the activation of several downstream repair mechanisms, including single-strand DNA breaks (SSBs), base-excision repair (BER), HR and NHEJ (Pilie et al., 2019). SIRTs and PARPs all require NAD⁺ to elicit function. However, PARP1 consumes NAD⁺, and this affects NAD⁺-dependent SIRT activity. Thus, depleting PARP1 increases the catalytic function of SIRTs (Schreiber et al., 2006; Houtkooper et al., 2012; Imai and Guarente, 2014). Under conditions of oxidative stress, SIRT6 physically binds to and mono-ADP-ribosylates PARP1 at K521 to facilitate DNA repair (Mao et al., 2011). SIRT7 is recruited to DSB sites in a PARP1-dependent manner, and catalyzes H3K122 desuccinylation, which facilitates chromatin compaction and DNA repair (Li et al., 2016). Based on synthetic lethality,
PARP inhibitors induce genomic instability in breast cancer susceptibility protein (BRCA1/2)-deficient cancer cells (Pilie et al., 2019). The combined use of HDAC and PARP inhibitors will likely be of great benefit for patients with BRCA1/2-deficient malignancies (Liszkczak et al., 2018).

With the exception of DSBs, cancer cells can overcome DNA damage-induced cytotoxicity through BER, nucleotide excision repair (NER) and mismatch repair. Uracil-DNA N-glycosylase isoform 2 (UNG2) has a role in BER and can be deacetylated at K78 by HDAC, boosting dissociation from its E3 ubiquitin-like containing PHD and ring finger domain 1 (UHRF1) when stimulated by ROS. HDAC3 combined with genotoxic agents results in UNG2 degradation, resulting in a robust cell death effect (Bao et al., 2020). SIRT1 interacts with xeroderma pigmentosum group A (XPA) in NER by directly deacetylating XPA or mediating XPA binding to ATR to prevent UV irradiation (Fan and Luo, 2010; Jarrett et al., 2018). HDAC10 is mainly involved in DNA mismatch repair by deacetylating mutS homolog 2 (MSH2) at K73 (Radhakrishnan et al., 2015).

Besides, a number of other histone modifications are also actively involved in these DNA repair pathways, but are beyond the scope of this review (Cao et al., 2016; Kim J. J. et al., 2019; Li Z. et al., 2019). Suffice to say that the multiple sites of H3 and H4 acetylation are not absolutely related to checkpoint activation because the conversion of lysine to other amino acids can still activate checkpoints (Robert et al., 2011).

**Cell Cycle**

Cell cycle dysregulation is a central hallmark of oncogenesis; as such, cell cycle regulators are considered promising targets for cancer treatment. HDACs are often involved in cell cycle checkpoints. HDAC3-mediated deacetylation of cyclin A affects the progression of the S phase and G2/M transitions (Bhaskara et al., 2008, 2010). HDAC10 depletion induces G2-M transition arrest through the regulation of cyclin A2. Mechanically, HDAC10 depletion induces the downregulation of high mobility group AT hook 2 (HMG2A), which leads to enrichment of E4F transcription factor 1 (a cyclin A2 repressor) at the cyclin A2 promoter and G2-M arrest (Li et al., 2015). Regarding combination therapies, the CDK9 inhibitor dinaciclib and panobinostat together induce apoptosis over the short-term in MLL-AF9-driven acute myeloid leukemia (AML) (Baker et al., 2016). The emerging hybrid inhibitor Roxyl-zhc-84, which concordantly inhibits HDACs and CDKs, induces G1-phase arrest and apoptosis in ovarian and breast cancer cells (Huang et al., 2018c).

Spindle assembly checkpoint (SAC) is involved in regulating mitosis. Budding uninhibited by benzyimidazol related-1 (BubR1), a component of the SAC, must be deacetylated by HDAC2/3 to initiate mitotic exit (Park et al., 2017). HDAC3 induces SAC activation and the dissociation of sister chromatids (Eot-Houllier et al., 2008). SIRT2 is strongly associated with mitosis exit (Dryden et al., 2003). SIRT2 regulates the anaphase-promoting complex/cyclosome (APC/C) by deacetylating its cofactors, cell division cycle protein 20 (CDC20) and CDC20 homolog 1 (CDH1), which are both required for mitosis exit and chromosome segregation (Kim et al., 2011). SIRT2 also deacetylates α-tubulin at K40 to promote cell mobility (North et al., 2003). The SIRT2 inhibitor SirReal2 induces tubulin hyperacetylation and BubR1 destabilization (Rumpf et al., 2015). HDAC5 induces the transcription of the mitosis kinase Aurora A, by repressing the expression of the E3 ligase NEDD4 (Sun et al., 2014). Combination of the Aurora A kinase inhibitor alisertib with romidepsin causes dose-dependent cytotoxicity of lymphoma cells (Zullo et al., 2015).

**Apoptosis**

Apoptosis is a physiologically programmed cell death pathway that is essential for the maintenance of organismal homeostasis. Apoptosis is controlled by the B-cell lymphoma 2 (Bcl-2) family of proteins, which includes both pro-survival and pro-apoptotic proteins that control cell fate (Singh et al., 2019).

Regarding the intrinsic apoptotic pathway, the Bcl-2 interacting mediator of cell death (Bim), a Bcl-2 homology 3 (BH3)-only proapoptotic protein, is upregulated by depsipeptide via FoxO1 acetylation (Yang et al., 2009). Panobinostat elevates Sry-box transcription factor 7 (SOX7) expression and suppresses lung cancer cell proliferation. Mechanically, SOX7 triggers apoptosis by preventing Bim from proteasome-mediated degradation (Sun et al., 2019). The N-terminal truncated form of p63, ΔNp63, belongs to the p53 family, but acts as an oncprotein. In squamous cell carcinoma, HDAC1 and HDAC2 form a complex with ΔNp63 to suppress the proapoptotic gene expression such as p53 upregulated modulator of apoptosis (PUMA) (Ramsey et al., 2011).

Histone deacetylase inhibitors treatment also affects the anti-apoptotic members of the Bcl-2 family. Specifically, depsipeptide induces apoptosis by decreasing the expression of pro-survival factors Bcl-2 and B-cell lymphoma-extra-large (Bcl-xl) (Adams and Eischen, 2016; Adams et al., 2016). The HDAC6-selective inhibitor ricolinostat exerts pronounced anti-lymphoma effects both alone and in combination with the alkylating agent bendamustine, by impairing the activation of caspase 8, -9, -3, and the Bcl-2 family (Cosenza et al., 2017). Myeloid cell
leukemia 1 (Mcl-1) is an E3-bound, anti-apoptotic protein that is involved in mitotic arrest (Senft et al., 2018). HDACi-induced Mcl-1 phosphorylation likely promotes apoptosis, whereas mutant phosphorylated Mcl-1 resists HDACi by binding to BH3-only proapoptotic proteins (Tong et al., 2018).

p53 is a crucial activator of apoptosis. HDAC1-3 all downregulate p53 activity, which represses p53-mediated activation of the pro-apoptotic gene BAX (Juan et al., 2000). Acetylation of p53 at K120 upregulates apoptotic peptidase activating factor 1 (Apaf-1) in the mitochondria (Yun et al., 2016). Under genotoxic stress, HDAC5 deacetylates p53 at K120, which activates pro-apoptotic target genes (Sen et al., 2013). Furthermore, HDAC6 directly deacetylates p53 at K120, which is required for p53-induced apoptosis in tumors with AT-rich interaction domain 1A (ARID1A) mutations (Bitler et al., 2017).

In summary, HDACi promote apoptosis via the intrinsic mitochondrial pathway, decreasing the expression of key anti-apoptotic factors (eg. Mcl-1, Bcl-2, and Bcl-xL), and/or increasing the expression of pro-apoptotic proteins (eg. BAX, Bim, Noxa and PUMA). HDACi also facilitate the activation of extrinsic apoptotic pathways, such as TRAIL (Nebbioso et al., 2017), driving mitochondrial outer membrane polarization (MOMP) and ultimately caspase-mediated cell death.

## Degradation System

The modulation of protein degradation is of critical importance for cell function. Protein degradation occurs via two major pathways: the ubiquitin-dependent proteasome pathway and autophagy system.

### Autophagy

Autophagy is a degradation process whereby autophagosomes engulf and recycle nutrient sources in response to energetic demands and organelle turnover (Mizushima et al., 2008; Mizushima, 2018). Autophagy can be effectively promoted by HDACs. For example, depletion of HDAC10 perturbs autophagy flux through increased LC3-II/I, and the accumulation of p62 and acidic vesicular organelles. HDAC10 inhibition results in increased sensitivity to cytotoxic reagents (Oehme et al., 2013). Sirt1 also forms complexes with autophagy related protein 5 (ATG5), ATG7 and ATG8 to promote autophagy, with organelles in Sirt1−/− mice being markedly damaged (Lee et al., 2008). The SIRT1 and -2 inhibitor tenovin-6 activates p53 and seems to be a specific regulator of mitochondrial acetylation (Lain et al., 2008; Scholz et al., 2015). Tenovin-6 suppresses Ewing sarcoma cells by regulating the NOTCH signaling pathway (Ban et al., 2014), and perturbs autophagic flux in chronic lymphocytic leukemia (CLL) cells and pediatric soft tissue sarcoma cells (Yuan et al., 2017). However, HDACs also interrupt autophagy, and various HDACi induce cancer cell death by promoting autophagy. In HDAC10-KO HeLa cells, chaperone-mediated autophagy (CMA) instead of macroautophagy is activated by the accumulation of lysosome-associated protein type 2A (LAMP2A)-positive lysosomes and the degradation of CMA substrate glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Obayashi et al., 2020). In response to serum starvation or oxidative stress, SIRT2 inhibition induces acetylated FoxO1 to locate in the cytoplasm, accelerating autophagy through interaction with ATG7 (Zhao et al., 2010). Under nutrient-rich conditions, FoxK1/2 bind to HDAC complex and restricts autophagic flux through the transcriptional repression of autophagy gene (Bowman et al., 2014). Under condition of nutrient deprivation, inhibition of the AKT serine/threonine kinase pathway facilitates nuclear import of FoxO3, which competitively replaces FoxK to bind the autophagy-associated gene promoters and upregulation of autophagy (Brunet et al., 1999; Bowman et al., 2014). Moreover, VPA activates autophagy by blocking HDAC1-mediated regulation of AKT pathway (Sun et al., 2020). The nutrient-sensor mammalian target of rapamycin (mTOR) negatively modulates downstream Unc-51-like autophagy activating kinase 1 (ULK1) that is involved in the non-transcriptional autophagic pathway. SAHA mTOR suppression, which ultimately activates autophagy by upregulating ULK1 (Gammoh et al., 2012). Of note, SAHA-induced autophagy seems to serve as a pro-survival mechanism to ameliorate SAHA-induced apoptosis by downregulating apoptotic factors (Gammoh et al., 2012). VPA also induces Sae2 [C-terminal-binding protein interacting protein (CtIP) in human] degradation in an autophagy related manner to impair HR-mediated DNA repair (Robert et al., 2011). As such, it seems that autophagy performs a dual role in DNA damage repair, depending on the cell states or DNA damage degree (Guo and Zhao, 2020).

### Proteasome-Dependent Degradation

In addition to autophagy, proteasome-dependent degradation is also critical for cell function. HDACs target various E3s to affect basal cellular function. For example, panobinostat upregulates the E3 cIAP2 that causes the ubiquitination and proteasomal degradation of MRE11, elevating cellular sensitivity to chemoradiation (Nicholson et al., 2017). HDAC6 also modulates aggresome formation and the clearance of polyubiquitinated and misfolded proteins (Kawaguchi et al., 2003). In terms of therapeutic development, suppressing the aggresome pathway results in the accumulation of misfolded proteins, causing autophagy-associated DNA damage and apoptosis of cancer cells (Rodriguez-Gonzalez et al., 2008). Proteasome inhibitors (PIs), such as the United States Food and Drug Administration (FDA)-approved bortezomib (BTZ), have similar roles in preventing the degradation of polyubiquitin-misfolded proteins, which increases the production of ROS and disturbs DNA repair in tumor cells (Perez-Galan et al., 2006). However, long-term treatment with BTZ leads to drug-resistance in most patients. Low concentrations of HDACi combined with BTZ can downregulate anti-apoptotic proteins and upregulate pro-apoptotic proteins, thus accelerating cell death (Dai et al., 2008; Wang J. et al., 2019). Combining the HDAC6-selective inhibitor tubacin with BTZ induces significant anti-tumor activity triggering c-Jun NH2-terminal kinase (JNK)-caspase signaling and endoplasmic reticulum (ER) stress (Hideshima et al., 2005; Nawrocki et al., 2006). Another HDAC6 inhibitor, WT161, promotes the accumulation of acetylated tubulin and overcomes BTZ resistance to promote multiple myeloma (MM) cell death (Hideshima et al., 2016). RTS-V5, a dual inhibitor
that targets HDAC6 and the 20S subunit of the proteasome, also possesses potent and selective anti-tumor activity in leukemia and MM cell lines (Bhatia et al., 2018).

Epithelial-Mesenchymal Transition, Cancer Stem Cells, and Senescence

Epithelial-mesenchymal transition (EMT) is characterized by the loss of the tight intercellular connections normally found in epithelial cells that then undergo cytoskeleton rearrangement and adopt the mesenchymal cell phenotype, which is associated with migration. Notably, cancer cell migration and invasion are promoted by a series of EMT-associated factors (such as SNAIL, ZEB, SLUG and TWIST) (Kim K. K. et al., 2018). These factors induce EMT-related stem cell properties and promote tumorigenesis via PTMs (Mani et al., 2008; Tam and Weinberg, 2013; Ye et al., 2015; Dai et al., 2020). S-nitrosylation of HDAC2 is regulated by endothelial nitric oxide synthase (eNOS) that is a crucial enzyme for NO synthesis, allowing ZEB1 re-activation (Cencioni et al., 2018). During hypoxia, HDAC3 is essential for the activation of mesenchymal gene expression by the interaction with WD repeat domain 5 (WDR5) (Wu et al., 2011). The transforming growth factor-β (TGF-β)-SMAD signaling pathway is the most important EMT stimulation pathway. HDAC6 also has an essential role in EMT by activating SMAD3 (Shan et al., 2008). SMAD3 and -4 induce SIRT7 transcriptional repression by forming a complex with HDAC8. HDAC8 inhibition significantly suppresses TGF-β signaling via SMAD-SIRT7 axis, and as a consequence, attenuates lung metastases of breast cancer (Tang et al., 2020). Class I HDACi 4SC-202 notably attenuates TGF-β-induced EMT (Mishra et al., 2017). By contrast, HDAC10 exhibits a potential TSG role by downregulating Sry-box transcription factor 9 (SOX9) in KRAS-driven lung adenocarcinoma. Furthermore, HDAC10 deficiency results in TGF-β pathway activation, leading to the induction of SOX9 and KRAS-expressing stem-like tumor growth (Li et al., 2020). Cancer-associated fibroblasts (CAFs) secrete extracellular matrix (ECM) that assists tumor progression and invasion. Scriptaid, a selective inhibitor of HDAC1, -3, and -8, represses TGF-β-mediated CAF by inhibiting ECM secretion and cell invasion (Kim D. J. et al., 2018). Of note, E-cadherin inhibits EMT, thus reduced E-cadherin expression indicates that "stemness" is increasing in cancer cells. HDAC and the 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) dual inhibitor JMF3086 restores E-cadherin expression and attenuates vimentin expression and stemness in NSCLC, which recovers sensitivity to gefitinib which is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) (Weng et al., 2019).

Cancer stem cells are hard to eradicate and prone to drug-resistance. HDAC3 interacts with p53 and forms complexes with tumor antigens melanoma antigen family A2 (MAGE-A2), establishing the resistance of melanoma cells to chemotherapeutic agents (Monte et al., 2006). In refractory and recurrent leukemia, HDAC8-selective inhibitor significantly restores acetylation and p53 activity, inducing apoptosis of AML cells but not of normal hematopoietic stem cells (Qi et al., 2015). In addition, SIRT1 inhibition increases the efficiency of BCR-ABL TKI imatinib mesylate to eliminate quiescent leukemia stem cells by reactivating p53 (Li et al., 2012).

Sirtuins are also closely involved in aging-related oncogene expression. Both SIRT6 and SIRT7 modulate long interspersed elements-1 (LINE-1, L1) expression and retrotransposition. SIRT6 mono-ADP-ribosylates the Krüppel-associated box domain-associated protein 1 (KAP1/TRIM28) and facilitates the KAP1 interaction with HP1a, resulting in the packaging of L1 elements into heterochromatin. SIRT7 directly binds L1 elements and promotes L1 sequences association with the nuclear lamina protein (Lamin A/C) by deacetylating H3K18 (Van Meter et al., 2014; Vazquez et al., 2019). These repressive functions of L1 highlight the protective roles of SIRTs on genome stability through preventing retrotransposition events. SIRT6 and SIRT7 deficiency result in aberrant heterochromatin and L1 activation especially in age-related diseases. Nucleoside reverse-transcriptase inhibitors can reverse a SIRT6 and SIRT7 deficiency by upregulating different immune signalings, such as the type I IFN pathway and cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway, respectively (Simon et al., 2019; Bi et al., 2020; Figure 4).

HDAC INHIBITORS IN CANCER THERAPY

In the 1970s, sodium butyrate was discovered to transform red leukemia cells into normal cells, and to resynthesize hemoglobin. This process was accompanied by strong histone hyperacetylation, and resulted in the discovery of the first HDACi (Ginsburg et al., 1973; Riggs et al., 1977; Vidali et al., 1978). In Tsuji et al. (1976) isolated the first natural HDACi, TSA, which was derived from Streptomyces hygroscopicus. Following the discovery of TSA, trapoxin was isolated from fungi and also found to act as an HDACi (Izatkanji et al., 1990). A number of natural inhibitors have since been extracted from fungi, marine life, and plants that contain sulfur, polyphenol, flavonoid, terpenoid, selenium, and other organic molecules (Newkirk et al., 2009; Lasciano et al., 2018; Singh et al., 2018). At present, HDACi are mainly divided into four categories following the FDA approval: (i) hydroxamic acids or hydroxamates, such as SAHA, panobinostat and belinostat; (ii) cyclic peptides, including depsipeptide; (iii) benamides, such as chidamide; and (iv) short-chain fatty acids, including VPA (Li and Zhu, 2014; Seto and Yoshida, 2014; Li and Seto, 2016; Table 3).

Efficiency of HDACi

From preclinical studies to clinical trials, HDACi have demonstrated powerful therapeutic effects in various cancers. HDACi can significantly attenuate tumor burden by limiting tumor growth and restraining aberrantly proliferated vessels (Guerriero et al., 2017). HDACi can also induce DNA damage, cell cycle arrest, apoptosis and autophagy to promote cancer cell death mentioned above. Some novel SIRT inhibitors, such as MC2494, MHY2245, MHY2256, tenovin-6, and YC8-02, also perform diverse anti-tumor activities through mediating...
apoptosis or autophagy (Carafa et al., 2018, 2019; De et al., 2018; Tae et al., 2018, 2020; Li M. et al., 2019; Igase et al., 2020).

Activation of the immune response by HDACi could also be an effective innate method to prevent cancer relapse when administered in a regimen with immunotherapeutic (Guerriero et al., 2017; Wang X. et al., 2020). The class IIa HDACi TMP195 efficiently improves the durability of tumor reduction in breast cancer by strengthening the phagocytic role of macrophages that are involved in the IFNγ axis; it also activates the adaptive anti-tumor immune response. Upon immune checkpoint blockade, TMP195 combined with an anti-programmed cell death-1 (PD-1) regimen could significantly reduce the tumor volume and induce a durable response in breast cancer (Guerriero et al., 2017). Myeloid-derived suppressor cells (MDSCs) suppress T-cell functions and promote tumor metastasis via the formation of an immunosuppressive tumor microenvironment (Azzaoui et al., 2018; De et al., 2018; Tae et al., 2018, 2020; Li M. et al., 2019; Igase et al., 2020).

Activation of the immune response by HDACi could also be an effective innate method to prevent cancer relapse when administered in a regimen with immunotherapeutic (Guerriero et al., 2017; Wang X. et al., 2020). The class IIa HDACi TMP195 efficiently improves the durability of tumor reduction in breast cancer by strengthening the phagocytic role of macrophages that are involved in the IFNγ axis; it also activates the adaptive anti-tumor immune response. Upon immune checkpoint blockade, TMP195 combined with an anti-programmed cell death-1 (PD-1) regimen could significantly reduce the tumor volume and induce a durable response in breast cancer (Guerriero et al., 2017). Myeloid-derived suppressor cells (MDSCs) suppress T-cell functions and promote tumor metastasis via the formation of an immunosuppressive tumor microenvironment (Azzaoui et al., 2018; De et al., 2018; Tae et al., 2018, 2020; Li M. et al., 2019; Igase et al., 2020).

**FIGURE 4** Overview of HDAC-involved biological functions and therapeutic targets. An overview of HDAC-involved biological functions including transcription, metabolism, oxidative stress, redox, protein degradation, cell cycle, DNA damage repair, apoptosis, angiogenesis, EMT, immunity, and stemness. There diverse functions could establish single or synergistic therapeutic targets.
TABLE 3 | Current clinical trials involving the use of HDAC inhibitors to treat cancer.

| Chemical class | Drug name (synonyms) | HDACs | Current status |
|----------------|----------------------|-------|----------------|
| Hydroxamic acids | Vorinostat (SAHA) | Class I, II, and IV | FDA (2006) |
|                 | Belinostat (PXD101; PX105684) | Class I, II, and IV | FDA (2014) |
|                 | Panobinostat (LBH589) | Class I, II, and IV | FDA and EMA (2015) |
|                 | Resminostat (RAS2410; 4SC-201) | Selective-HDAC1, -3, -6 | Phase II |
|                 | Givinostat (TP2357) | Selective-HDAC1, -3 | Phase II |
|                 | Pracinostat (SB939) | Classes I, II, and IV but except HDAC6 | Phase II/III |
|                 | Abelosinostat (CRA 024781; PCI-24781) | Class I and HDAC10 | Phase II/III |
|                 | Quisinostat (INJU-26481585) | Class I, II, and IV | Phase I |
|                 | MPT0E028 | HDAC1, -2, -3, -6, -10 and class I PIBK | Phase I |
|                 | Nanatinostat (CHR-3996) | HDAC1-3 | Phase I |
|                 | CUDC 101 | Class I and II HDAC, EGFR and HER2 | Phase I |
|                 | Fimepinostat (CUDC-907) | HDAC1, -2, -3, -6, -10 and class I PIBK | Phase I |
| Benzamides | Chidamide (Tucidinostat; HBI-8000; Epidaza) | HDAC1, -2, -3, -10 | Chinese FDA (2015) |
|                 | Entinostat (MS-275) | HDAC1-3 | Phase II/III |
|                 | Rocloinostat/Ricolinostat (ACY1215) | Selective-HDAC6 | Phase II |
|                 | Tacedinaline (N-acetyldinaline; CI-994) | HDAC1-3 | Phase II/III |
|                 | Mocetinostat (MGCD0103) | HDAC1, -2, -3, -11 | Phase II/III |
|                 | Domatinostat (4SC-202) | HDAC1, -2, -3, -5, 9, -10, -11 and LSD1 | Phase II/III |
| Cyclic peptides | Romidepsin (FK 228; FR 901228; NSC 630176) | HDAC1, -2, -4 | FDA (2009) |
| Fatty acids | Valproic acid | Class I, II | Phase I/II/III/IV |
|                 | AR-42 (OSU-HDAC42) | Class I and IIb | Phase I |
|                 | Pravanex (AN-9) | Class I and II | Phase II |
|                 | Sodium phenylbutyrate | HDAC and ER stress | Phase I/II |
| Sirtuins | Nicotinamide | SIRTs | Phase III |
| Others | CXD101 | HDAC1-3 | Phase II |
|                 | EDO-S101 (Tinostamustine) | Class I, IIb | Phase I/II |
|                 | Citarinostat (ACY241) | Class I, HDAC10 | Phase I |
|                 | R306465 | HDAC1, -8 | Phase I |

FDA, Food and Drugs Administration; EMA, European Medicines Agency.

2016; Betsch et al., 2018). Entinostat exhibits remarkable curative effects when combined with PD-1 and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blockade; it has been shown to significantly reduce the number of MDSCs (Kim et al., 2014). 5-azacytidine combined with entinostat can also suppress MDSCs by downregulating C-C chemokine receptor type 2 (CCR2) and C-X-C chemokine receptor type 2 (CXCR2) expressions that ultimately, stimulates MDSC differentiation into a macrophage-like phenotype (Lu Z. et al., 2020). In human epidermal growth-factor receptor 2-positive (HER2+1) breast cancer, panobinostat combined with trastuzumab (anti-HER2) stimulates the release of CXCR3-reactive chemokines and enhances the recruitment of tumor-associated natural killer (NK) cells to achieve eradication of tumors (Medon et al., 2017).

The first FDA-approved HDAC inhibitor, SAHA, belongs to the hydroxamic acid class, approved to treat patients with cutaneous T cell lymphoma (CTCL). In many clinical trials, SAHA has proven effective against advanced and refractory tumors, alone or in combination with other inhibitors. Subsequently, the cyclic peptide romidepsin was approved by the FDA in 2009 to treat CTCL. Panobinostat and belinostat were both approved by the FDA in 2014 to treat peripheral T cell lymphoma (PTCL), with belinostat gaining additional approval from the European Medicines Agency (EMA). Both panobinostat and belinostat are classified as hydroxamic acids. Meanwhile, chidamide has become the first benzamide HDACi to be approved by the China Food and Drug Administration (CFDA) in 2015, for the treatment of relapsed and refractory PTCL1,2,3,4. Most SIRT inhibitors still remain in the preclinical stages. So far, only nicotinamide (vitamin B3) has been used to treat cancer in clinical trials (e.g., NCT02416739 and NCT00033436). Nicotinamide has shown a potential role in inhibiting non-melanoma skin cancers that are principally generated by UV (Chen et al., 2015). Compared to other HDACi, nicotinamide exhibits the most catalytic sites: it is predominantly sensitive to acetylation sites in nuclear proteins that are involved in diverse biological processes (Scholz et al., 2015).

Application of Selective Inhibitors and Combination Therapy

With the development of HDACi, numerous clinical trials are ongoing or completed currently for cancer therapy. Many HDACi have already been approved for hematomal malignancies and
### TABLE 4 | Clinical trials investigating the single-agents or combined therapies in HDACi and other anti-neoplastic drugs.

| HDACi | Synergetic drugs (targets) | Clinical trial phase | Cancer specificity | Clinical registration number |
|-------|---------------------------|----------------------|-------------------|-----------------------------|
| Vorinostat (SAHA, Zolinza) | – | Phase I/II (finished) | pediatric (3–18 years) relapsed solid tumor, lymphoma and leukemia; well-tolerant; basal safe dose recommendation (SDR) of 130 mg/m²/day with weekly dose escalation was determined | NCT01422499 |
| Mogamulizumab (anti-CCR4 monoclonal antibody) | – | Phase I (finished) | CTCL; Mogamulizumab significantly prolongs progression-free survival compared with vorinostat | NCT00719875 |
| Hydroxychloroquine (autophagy inhibitor) | – | Phase I (finished) | Advanced renal and CRC; safety and preliminary efficacy; establishes maximum tolerated dose (MTD) HCQ and vorinostat | NCT01023737 |
| Belinostat (PXD-101) | Cisplatin (Chemotherapy), Etoposide (Topoisomerase II inhibitor) | Phase I (finished) | Small Cell Lung Cancer and Neuroendocrine Cancers; 48’h infusion with cisplatin plus etoposide shows safety and activity | NCT00926640 |
| – | Warfarin (anticoagulation) | Phase I (finished) | Solid Tumors or Hematological Malignancies; cannot affect the pharmacokinetics and pharmacodynamics of warfarin | NCT01317927 |
| Entinostat (MS-275, NSC 706995) | Ibrutinomab tuxetan/Zevalin (anti-CD20 monoclonal antibody) | Phase II (finished) | Aggressive lymphomas; establishes clinical biomarkers but cannot achieve overall response rate (ORR) | NCT01686165 |
| – | Sargramostim (GM-CSF) | Phase II (finished) | Relapsed and refractory myeloid malignancies; well tolerated and efficacious clinical activity but lack of longer observation periods | NCT00462605 |
| Aidesleukin (interleukin-2, IL2) | Trastuzumab (anti-HER2+) | Phase I/II | metastatic clear cell renal cell carcinoma (ccRCC); improves progression-free survival and overall survival | NCT01038778 |
| – | Exemestane (steroidal aromatase inhibitor) | Phase III (finished) | Tucidinostat plus exemestane improves progression-free survival in patients with advanced, hormone receptor (+), HER2 (−) breast cancer that failed and progressed after previous endocrine therapy | NCT02482753 |
| Panobinostat (LBH 589) | bortezomib, thalidomide (immunosuppressive and anti-angiogenic activity) and dexamethasone | Phase I / II | refractory or relapsed MM; well-tolerant; takes orally 20 mg as SDR with escalation schedule | NCT02145715 |
| – | bortezomib and dexamethasone | Phase I / II | relapsed and refractory MM; improves patients’ outcomes; overall survival benefits with panobinostat over placebo with bortezomib and dexamethasone | NCT01023308 |
| Bicalutamide/Casodex (androgen receptor antagonist) | – | Phase I / II (finished) | Castration-resistant prostate cancer; well tolerated and increased radiographic progression-free survival | NCT00879436 |
| Chidamide (Tucidinostat, Epidaza) | Exemestane | Phase III (finished) | Tucidinostat plus exemestane improves progression-free survival in patients with advanced, hormone receptor (+), HER2 (−) breast cancer that failed and progressed after previous endocrine therapy | NCT02482753 |
| – | Ruximab (murine-derived monoclonal antibody binds CD20), Venetoclax (Bcl-2 inhibitor), Bendamustine (alkylated DNA crosslinker) | Phase I | Relapsed or refractory DLBCL; tolerable safety and durable anti-tumor activity particularly in MYC-driven patients | NCT01742988 |
| Fimepinostat (CUDC-907), (PI3K and HDAC inhibitor) | – | Phase I (finished) | Performs good safety and tolerability; orally administers the schedule 5 days followed by a 2-day break (5/2) at 60 mg in refractory or relapsed lymphoma or MM | NCT02674750 |
| ACY-1215 | Lenalidomide (immunomodulator) | Phase Ib | relapsed or refractory MM, safe, well-tolerated | NCT01583283 |
| – | dexamethasone bortezomib and dexamethasone | Phase I / II | relapsed or refractory MM, safe, well-tolerated, and active | NCT01323751 |

*“–” means monotherapy; Clinical trials mainly derived from United States National Library of Medicine.*
lymphomas, while clinical studies are ongoing for refractory, advanced and recurrent solid tumors (Table 4). For instance, the use of the HDAC6-selective inhibitor ACY1215 (also named rocilinostat or ricolinostat) as a regimen for relapsed or refractory lymphoma and MM is currently in phase I/II clinical trials [Lymphoma (NCT02091063), MM (NCT01323751, NCT01583283, NCT01997840)]. HDACi with multiple targets have also been developed and tested in clinical trials, such as the dual HDAC and phosphoinositide-3 kinase (PI3K) inhibitor CUDC-907 (also called fimepinostat), which has been reported to inhibit Myc transcriptional expression and reduce Myc-mediated proliferation of multiple cancer cell lines (Pei et al., 2016; Kotian et al., 2017; Pal et al., 2018; Guo et al., 2019). The safety, tolerability and efficacy of CUDC-907 has been assessed in phase I/II trials (Younes et al., 2016). CUDC-101 is another multiple-target inhibitor that blocks HDACs, the epidermal growth factor receptor (EGFR) and HER2 in head and neck squamous cell cancer (Galloway et al., 2015).

Combination drugs can inhibit tumorigenesis from different aspects. A clinical phase I trial of SAHA combined with the autophagy inhibitor MLN9708 shows potential for this regimen in advanced p53-mutant malignancies (NCT02042989). Hydroxychloroquine (HCQ) is a common autophagy-targeting reagent that has been used in clinical research (Mahalingam et al., 2014). Several phase I/II clinical studies (e.g., NCT02316340 and NCT01023737) have thus tested the safety, tolerability and pharmacological efficacy of SAHA combined with HCQ in solid tumors. A phase I/II trial targeting BTZ-resistant MM cancer has found that a synergistic regimen of using ricolinostat and dexamethasone could be safe and well-tolerated in affected patients (Vogl et al., 2017). A recent phase III clinical trial found that a combination of chidamide and exemestane has therapeutic potential for postmenopausal patients with advanced, hormone receptor-positive (HR+), HER2- breast cancer and who have failed to respond to endocrine therapy (Jiang et al., 2019). Combining the SIRT1 inhibitor Ex527 with the WEE1 inhibitor MK-1775 produces efficient effects in lung cancers by impairing HR repair and mitotic catastrophe-associated apoptosis (Chen et al., 2017).

The overall survival (OS) and progression-free survival (PFS) are common and quite important indicators in the clinical trials. A phase I/II clinical study targets patients with metastatic clear cell renal cell carcinoma (ccRCC) by treatment with entinostat and high-dose interleukin-2 (IL2) that downregulates forkhead box P3 (Foxp3) expression and function of regulatory T cells (Treg). The median PFS reaches 13.8 months, and the median OS is 65.3 months (Pili et al., 2017) [NCT01038778]. A phase III trial enrolled 768 patients with relapsed MM exhibits that panobinostat shows the median OS of panobinostat (40.3 months) versus that of placebo (35.8 months) based on the existing treatments of bortezomib and dexamethasone. And patients who had received previous regimens such as immunomodulatory drug and bortezomib, median OS was only 25.5 months when received panobinostat, bortezomib, and dexamethasone versus that was merely 19.5 months who received placebo (San-Miguel et al., 2016) [NCT01023308]. These HDACi significantly exhibit potential median OS and PFS for patients with advanced tumors.

**Limitations of HDACi**

However, in a randomized, double-blind and placebo-controlled phase III trial, vorinostat did not improve OS and could not be recommended as a therapy as a second-line or third-line drug for patients with advanced malignant pleural mesothelioma (Krug et al., 2015). Moreover, a phase III study that recruited 370 patients with Sézary syndrome or relapsed or refractory mycosis fungoides in CTCL from different countries of the world showed that the overall response rate to vorinostat was less efficient than that to mogamulizumab, a novel monoclonal antibody against CCR4 that significantly prolongs PFS (Kim Y. H. et al., 2018). The overall response to vorinostat in this study was significantly lower than reported in a previous study (Olsen et al., 2007). Besides, in a phase II trial, mocetinostat did not reverse chemoresistance in patients with previous gemcitabine-resistant leiomyosarcoma and could not significantly prolong the median PFS of patients (Choy et al., 2019).

Sirtuins constitute a relatively unique class of HDACs; as such, SIRT modulators are attracting great interest in the research community (Yang et al., 2017; Dai et al., 2018; Wang Y. et al., 2019). A novel SIRT7 inhibitor has been identified to inhibit tumor growth by blockade of the direct interaction of SIRT7 and p53 (Vakhrusheva et al., 2008; Kim J. H. et al., 2019). However, there are also several reports demonstrating an indirect interaction between SIRT7 and p53 (Barber et al., 2012; Lu Y. F. et al., 2020; Yu et al., 2020). Thus, it is urgent to develop specific SIRT inhibitors for cancer therapy according to reasonable mechanisms. It is worth noting that SIRT activators and sirtuin-activating compounds (STACs) have been developed and studied in clinical trials to investigate their anti-aging, anti-inflammatory and metabolic regulatory effects (Howitz et al., 2003; Hubbard et al., 2013; Sinclair and Guarente, 2014; Bonkowski and Sinclair, 2016; Carafa et al., 2016; Huang et al., 2018b). Nevertheless, the SIRT1 activator SRT2183 has also been shown to inhibit growth and to promote cell death by causing ER stress in glioma cells (Ye et al., 2019).

Besides, most of clinical trials of HDACi have reported many adverse effects, including bleeding caused by different grades of thrombocytopenia, susceptibility to infection caused by neutropenia, anemia caused by hemoglobin reduction, arrhythmia, myocardial hypertrophy, neurotoxicity, and gastrointestinal toxicity such as nausea, vomiting, fatigue, diarrhea as well as electrolyte disturbance such as hypophosphatemia and hyponatremia. The most adverse effect reported is cell death caused by continuous cytotoxicity (Medina et al., 1997; Zhu et al., 2001b), as these agents also kill immortalized and normal cells from different tissues (Lee et al., 1996; Burgess et al., 2004).

**DISCUSSION AND PERSPECTIVES**

To date, only five HDACi have been approved by health authorities globally. Numerous clinical trials are currently evaluating the safety, application, and therapeutic benefits of HDAC inhibition when treating cancers, neurological disorders and other human diseases. Thus far, it is clear that FDA-approved
HDACi have both beneficial and adverse effects. These effects might be accompanied by genomic instability, abnormal gene transcription, interference with chaperone protein function and free radical generation, which currently limit the therapeutic potential of HDACi.

Analyses of HDAC structural conformations and molecular mechanisms are necessary to improve treatment development. Complicating the application of HDACi is that the modification of the substrates by HDAC has spatio-temporal and tissue specificity. Consequently, dose-dependent and time-dependent treatments have different effects on gene expression regulation, various protein PTMs and chromatin remodeling. For now, combining different drugs to inhibit pathways such as tumor proliferation or angiogenesis, or to stimulate apoptosis requires more consideration.

Isolating the anti-cancer effects of HDACi and then synthesizing molecules with highly specific targets could be a promising avenue for cancer treatment in the future. Further investigation into combination treatments involving oncoprotein inhibitors and specific HDACi is also warranted. Overall, it seems that combination therapies have the advantage of reducing drug toxicity and lowering dose demand. SIRT protective factors should also be considered. Pending additional work to clarify HDACi that target specific HDACs or can be combined with other treatments, such as DNA methylation inhibitors or autophagy inhibitors, could be of great benefit to patients with cancers that have failed to respond to conventional treatments.

AUTHOR CONTRIBUTIONS

GL wrote the primary manuscript and YT revised the manuscript. W-GZ conceived and designed the manuscript. All authors contributed to the article and approved the submitted version.

FUNIDNG

This work was supported by the National Key R&D Program of China (Grant No. 2017YFA0503900), Science and Technology Program of Guangdong Province in China (2017B030301016), Shenzhen Municipal Commission of Science and Technology Innovation (JCYJ20170818092459091), and Discipline Construction Funding of Shenzhen [(2016)1452].

ACKNOWLEDGMENTS

We are grateful to Dr. Jessica Tamanini (Shenzhen University) for proofreading the manuscript. We apologize to those whose works are not cited here due to limited space.

REFERENCES

Adams, C. M., and Eischen, C. M. (2016). Histone deacetylase inhibition reveals a tumor-suppressive function of MYC-regulated miRNA in breast and lung carcinoma. Cell Death Differ. 23, 1312–1321. doi: 10.1038/cdd.2016.9
Adams, C. M., Hiebert, S. W., and Eischen, C. M. (2016). Myc induces miRNA-mediated apoptosis in response to HDAC inhibition in hematologic malignancies. Cancer Res. 76, 736–748. doi: 10.1158/0008-5472.can-15-1751
Agraval, N., Mephoston, J. P., Bailey, H., Gupta, S., Werner, T. L., Reddy, G., et al. (2016). A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin. Cancer Chemother. Pharmacol. 77, 299–308. doi: 10.1007/s00280-015-2934-1
Agro, T., Liu, T., Zhai, P., Chen, W., Li, H., Molkentin, J. D., et al. (2008). A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell 133, 978–993. doi: 10.1016/j.cell.2008.04.041
Ahn, B. H., Kim, H. S., Song, S., Lee, I. H., Liu, J., Vassilopoulos, A., et al. (2008). A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc. Natl. Acad. Sci. U.S.A. 105, 14447–14452. doi: 10.1073/pnas.0803790105
Alexandrova, E. M., Yallowitz, A. R., Li, D., Xu, S., Schulz, R., Proia, D. A., et al. (2012). ADAMTS13 inhibits thrombus formation in vitro and in vivo. Blood 119, 2591–2600. doi: 10.1182/blood-2011-08-362783
Ali, I., Ruiz, D. G., Ni, Z., Johnson, J. R., Zhang, H., Li, P. C., et al. (2019). Crosstalk between RNA Pol II C-terminal domain acetylation and phosphorylation via RPRD Proteins. Mol. Cell 74, 1164–1174.e4
Allfrey, V. G., Faulkner, R., and Mirsky, A. E. (1964). Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc. Natl. Acad. Sci. U.S.A. 51, 786–789. doi: 10.1073/pnas.51.5.786
Amano, H., Chaudhury, A., Rodriguez-Aguayo, C., Lu, L., Akhanov, V., Catic, A., et al. (2019). Telomere dysfunction induces sirtuin repression that drives telomere-dependent disease. Cell Metab. 29, 1274–1290.e9
Anastas, J. N., Zee, B. M., Kalin, J. H., Kim, M., Guo, R., Alexandrescu, S., et al. (2019). Re-programming Chromatin with a Bifunctional LSD1/HDAC inhibitor induces therapeutic differentiation in DIPG. Cancer Cell 36, 528–544.e10.
Anderson, K. A., Huynh, F. K., Fisher-Wellman, K., Stuart, J. D., Peterson, B. S., Douros, J. D., et al. (2017). SIRT4 is a lysine deacetylase that controls leucine metabolism and insulin secretion. Cell Metab. 25, 838–855.e15.
Aramsangtiengchai, P., Spiegelman, N. A., He, B., Miller, S. P., Dai, L., Zhao, Y., et al. (2016). HDAC8 Catalyzes the Hydrolysis of Long Chain Fatty Acyl Lysine. ACS Chem. Biol. 11, 2685–2692. doi: 10.1021/acscmbio.6b00396
Ardephan, P. M., and Liang, F. (2012). Cell. 133, 978–993. doi: 10.1016/j.cell.2016.9
Ayer, D. E. (1999). Histone deacetylases: transcriptional repression with SINers and NuRDs. Trends Cell Biol. 9, 193–198. doi: 10.1016/S0962-8924(99)01536-6
Azagra, A., Roman-Gonzalez, L., Collazo, O., Rodriguez-Ubreva, J., De Yebenes, V. G., Barneda-Zahonero, B., et al. (2016). In vivo conditional deletion of HDAC7 reveals its requirement to establish proper B lymphocyte identity and development. J. Exp. Med. 213, 2591–2601. doi: 10.1084/jem.20150821
Azouz, I., Uhel, F., Rossille, D., Panguault, C., Dulong, J., Le Priol, J., et al. (2016). T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. Blood 128, 1081–1092. doi: 10.1182/blood-2015-08-662783
Bagchi, R. A., Ferguson, B. S., Stratton, M. S., Hu, T., Cavassin, M. A., Sun, L., et al. (2018). HDAC11 suppresses the thermogenic program of adipose tissue via BRD2. JCI Insight 3:e120159.
Baker, A., Gregory, G. P., Verbruggge, I., Kats, I., Hilton, J. J., Vidacs, E., et al. (2016). The CDK9 inhibitor dinaciclib exerts potent apoptotic and antitumor effects in preclinical models of mll-rearranged acute myeloid leukemia. Cancer Res. 76, 1158–1169. doi: 10.1158/0008-5472.can-15-1070
Balasubramaniam, S., Redon, C. E., Peer, C. J., Bryla, C., Lee, M. J., Trepel, J. B., et al. (2018). Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung. Anticancer Drugs 29, 457–465.
Ban, J., Aryee, D. N., Fourtouna, A., Van Der Ent, W., Kauer, M., Niedan, S., et al. (2011). Chemoproteomics profiling of HDAC inhibitors reveals selective conventional treatments.

Author Contributions

GL wrote the primary manuscript and YT revised the manuscript. W-GZ conceived and designed the manuscript. All authors contributed to the article and approved the submitted version.

Funidng

This work was supported by the National Key R&D Program of China (Grant No. 2017YFA0503900), Science and Technology Program of Guangdong Province in China (2017B030301016), Shenzhen Municipal Commission of Science and Technology Innovation (JCYJ20170818092459091), and Discipline Construction Funding of Shenzhen [(2016)1452].
targeting of HDAC complexes. *Nat. Biotechnol.* 29, 255–265. doi: 10.1038/nbt.1759

Bao, J., Lu, Z., Joseph, J. J., Carabencov, D., Dimond, C. C., Pang, L., et al. (2010). Characterization of the murine SIRT3 mitochondrial localization sequence and comparison of mitochondrial enrichment and deacetylation activity of long and short SIRT3 isoforms. *J. Cell. Biochem.* 110, 238–247.

Bao, X., Liu, Z., Zhang, W., Gladysz, K., Fung, Y. M. E., Tian, G., et al. (2019). Glutarylation of histone H4 Lysine 91 regulates chromatin dynamics. *Mol. Cell* 76, 660–675.e9.

Bao, Y., Tong, L., Song, B., Liu, G., Zhu, Q., Lu, X., et al. (2020). UNG2 deacetylation confers cancer cell resistance to hydrogen peroxide-induced cytotoxicity. *Free Radic. Biol. Med.* 160, 403–417. doi: 10.1016/j.freeradbiomed.2020.06.010

Barber, M. F., Michishita-Kioi, E., Xi, Y., Tasselli, L., Kioi, M., Moqtaderi, Z., et al. (2012). SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. *Nature* 487, 114–118. doi: 10.1038/nature11043

Barker, H. E., Paget, I. T., Khan, A. A., and Harrington, K. J. (2015). The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. *Nat. Rev. Cancer* 15, 409–425. doi: 10.1038/nrcc3958

Bertos, N. R., Gilquin, B., Chan, G. K., Yen, T. J., Khochbin, S., and Yang, X. J. (2004). Role of the tetradecapeptide repeat domain of human histone deacetylase 6 in cytoplasmic retention. *J. Biol. Chem.* 279, 48246–48254. doi: 10.1074/jbc.m40853200

Betsch, A., Rutgers, O., Fevery, S., Sprangers, B., Verhoef, G., Dierickx, D., et al. (2018). Myeloid-derived suppressor cells in lymphoma: the good, the bad and the ugly. *Blood* 132, 490–498. doi: 10.1182/blood.2018.04.0056

Bhardwaj, A., and Das, S. (2016). SIRT6 deacetylates PKM2 to suppress its nuclear localization and oncogenic functions. *Proc. Natl. Acad. Sci. U.S.A.* 113, E538–E547.

Bhaskara, S., Chyla, B. J., Amann, J. M., Knutson, S. K., Cortez, D., Sun, Z. W., et al. (2010). Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. *Mol. Cell* 30, 61–72. doi: 10.1016/j.molcel.2008.02.030

Bhaskara, S., Knutson, S. K., Ji, Q., Chandrasekharan, M. B., Wilson, A. J., Zheng, S., et al. (2010). Hdaec3 is essential for the maintenance of chromatin structure and genome stability. *Cancer Cell* 18, 436–447. doi: 10.1016/j.ccr.2010.10.022

Bhatia, S., Krieger, V., Groll, M., Osko, J. D., Resing, N., Ahlert, H., et al. (2018). Discovery of the first-in-class dual histone deacetylase-proteasome inhibitor. *J. Med. Chem.* 61, 10299–10309. doi: 10.1021/acs.jmedchem.8b00484

Bi, S., Liu, Z., Wu, Z., Wang, Z., Liu, X., Wang, S., et al. (2020). SIRT7 antagonizes human stem cell aging as a heterochromatin stabilizer. *Protein Cell* 11, 483–504. doi: 10.1007/s13238-020-00728-4

Biller, B. G., Wu, S., Park, P. H., Hai, Y., Aird, K. M., Wang, Y., et al. (2017). ARID1A-mutated ovarian cancers depend on HDAC6 activity. *Nat. Cell Biol.* 19, 962–973. doi: 10.1038/ncb3582

Blackford, A. N., and Jackson, S. P. (2017). ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. *Mol. Cell* 66, 801–817. doi: 10.1016/j.molcel.2017.05.015

Blank, M. F., Chen, S., Poetz, F., Schnolzer, M., Voit, R., and Grummt, I. (2017). SIRT7-dependent deacetylation of CDK9 activates RNA polymerase II transcription. *Nucleic Acids Res.* 45, 2675–2686. doi: 10.1093/nar/gkx053

Bonkowski, M. S., and Sinclair, D. A. (2016). Slowing ageing by design: the rise of Sirtuin functions and modulation: from chemistry to the clinic. *Clin. Epigenetics* 8:61.

Castanededa, C. A., Wolfson, N. A., Leng, K. R., Kuo, Y. M., Andrews, A. J., and Guarente, L. (2015). The multifaceted functions of sirtuins in cancer. *Nat. Cell Biol.* 17, 103–107. doi: 10.1038/ncll.2015.11103

Chatterjee, T. K., Idelman, G., Blanco, V., Blomkalns, A. L., Piegore, M. G. Jr., et al. (2013). Glutaredoxin regulates vascular development by reversible glutaredoxylation of sirtuin 1. *Proc. Natl. Acad. Sci. U.S.A.* 110, 20057–20062. doi: 10.1073/pnas.1313753110

Chen, A. C., Martin, A. J., Choy, B., Fernandez-Penas, P., Dalziell, R. A., Mckenzie, N., et al. (2015). A Phase 3 randomized trial of nicotinamide for skin-cancer modulators against cancer. *Oncogene* 34, 2864–2870. doi: 10.1038/onc.2014.286

Chen, G., Zhang, B., Xu, H., Sun, Y., Shi, Y., Luo, Y., et al. (2017). Suppression of Sirt1 sensitizes lung cancer cells to WEE1 inhibitor MK-1775-induced DNA damage and apoptosis. *Oncogene* 36, 6863–6872. doi: 10.1038/onc.2017.297

Chung, S., Young, B. D., Li, S., Qi, X., Richardson, J. A., and Olson, E. N. (2006). Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. *Cell* 126, 321–334. doi: 10.1016/j.cell.2005.05.040

Chatterjee, T. K., Idelman, G., Blanco, V., Blomkalns, A. L., Piego, M. G. Jr., Weintraub, D. S., et al. (2011). Histone deacetylase 9 is a negative regulator of adipogenic differentiation. *J. Biol. Chem.* 292, 21568–21577. doi: 10.1074/jbc.m111.110316

Cenciorgn, C., Spallotta, F., Savoia, M., Kuenne, C., Guenther, S., Re, A., et al. (2018). Zeb1-Hdac2-eNos circuitry identifies early cardiovascular precursors in naive mouse embryonic stem cells. *Nat. Commun.* 9:1281.

Chalkiadaki, A., and Guarante, L. (2015). The multifaceted functions of sirtuins in cancer. *Nat. Rev. Cancer* 15, 608–624. doi: 10.1038/nrc3985

Chang, S., Young, B. D., Li, S., Qi, X., Richardson, J. A., and Olson, E. N. (2006). Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. *Cell* 126, 321–334. doi: 10.1016/j.cell.2005.05.040

Chen, A. C., Martin, A. J., Choy, B., Fernandez-Penas, P., Dalziell, R. A., Mckenzie, N., et al. (2015). A Phase 3 randomized trial of nicotinamide for skin-cancer prevention. *N. Engl. J. Med.* 373, 1618–1626.

Chen, G., Zhang, B., Xu, H., Sun, Y., Shi, Y., Luo, Y., et al. (2017). Suppression of Sirt1 sensitizes lung cancer cells to WEE1 inhibitor MK-1775-induced DNA damage and apoptosis. *Oncogene* 36, 6863–6872. doi: 10.1038/onc.2017.297
Chen, L., Zhang, Z., Hoshino, A., Zheng, H. D., Morley, M., Arany, Z., et al. (2019). NADPH production by the oxidative pentose-phosphate pathway supports folate metabolism. Nat. Metab. 1, 404–415. doi: 10.1038/s42255-019-0043-x

Chen, X., Barozzi, I., Termanini, A., Prosperi, E., Recchiuti, A., Dalli, J., et al. (2012). Requirement for the histone deacetylase Hda3 for the inflammatory gene expression program in macrophages. Proc. Natl. Acad. Sci. U.S.A. 109, E2865–E2874.

Chen, X. F., Tian, M. X., Sun, R. Q., Zhang, M. L., Zhou, L. S., Jin, L., et al. (2018). SIRT5 protects peroxisomal ACOX1 to prevent oxidative damage and is downregulated in liver cancer. EMBO Rep. 19:e45124.

Choi, S. J., Lee, H. C., Kim, J. H., Park, S. Y., Kim, T. H., Lee, W. K., et al. (2016). HDAC6 regulates cellular viral RNA sensing by deacetylation of RIG-I. EMBO J. 35, 429–442. doi: 10.15252/embj.201592586

Choy, E., Ballman, K., Chen, J., Dickson, M. A., Chugh, R., George, S., et al. (2019). Corrigendum to “SARC018, SPORE02: phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomysarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy.” Cancer Res. 2019;76:8783.

Cimen, H., Han, M. J., Yang, Y., Tong, Q., Koc, H., and Koc, E. C. (2010). Regulation of succinate dehydrogenase activity by SIRT3 in mammalian mitochondria. Biochemistry 49, 304–311. doi: 10.1021/bi091627u

Cohen, H. Y., Miller, C., Bitterman, K. J., Wall, N. R., Hekking, B., Kessler, B., et al. (2019). Regulation of sirtuin responses to increased NAD(+) availability in response to fasting. Aging Cell 18, 917–929. doi: 10.1111/acel.13065

De, U., Son, J. Y., Sachan, R., Park, Y. J., Kang, D., Yoon, K., et al. (2018). A SIRT5-dependent protein lysine demalonylase and desuccinylase. Science 334, 806–809. doi: 10.1126/science.1207861

El-Naggar, A. M., Somasekharan, S. P., Wang, Y., Cheng, H., Negri, G. L., Pan, M., et al. (2019). Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis. EMBO Rep. 20:e48375.

Emiliani, S., Fischle, W., Van Lint, C., Al-Abed, Y., and Verdin, E. (1998). Characterization of a human RPD3 ortholog, HDAC3. Proc. Natl. Acad. Sci. U.S.A. 95, 2795–2800. doi: 10.1073/pnas.95.6.2795

Emmett, M. J., and Lazar, M. A. (2019). Integrative regulation of physiology by histone deacetylation 3. Nat. Rev. Mol. Cell Biol. 20, 102–115. doi: 10.1038/s41580-018-0076-0

Eom, G. H., Nam, Y. S., Oh, J. G., Choe, N., Min, H. K., Yoo, E. K., et al. (2014). Regulation of acetylation of histone deacetylase 2 by p300/CBP-associated factor/histone deacetylase 5 in the development of cardiac hypertrophy. Circ. Res. 114, 1133–1143. doi: 10.1161/circresaha.114.303429

Eot-Houllier, G., Fulcrand, G., Watanabe, Y., Magagnhi-Jaulin, L., and Jaulin, C. (2008). Histone deacetylase 3 is required for centromeric H3K4 deacetylation and sister chromatid cohesion. Genes Dev. 22, 2639–2644. doi: 10.1101/gad.484108

Etchegaryar, J. P., Chavez, L., Huang, F., Ross, K. N., Choi, J., Martinez-Pastor, B., et al. (2015). The histone deacetylase SIRT6 controls embryonic stem cell fate via TET-mediated production of 5-hydroxymethylcytosine. Nat. Cell Biol. 17, 545–557. doi: 10.1038/nch3147

Etchegaryar, J. P., Zhong, L., Li, C., Henriques, T., Ablondi, E., Nakadai, T., et al. (2019). The histone deacetylase SIRT6 restrains transcription elongation via promoter-proximal pausing. Mol. Cell 75, 683–699.e7

Falkenberg, K. J., and Johnstone, R. W. (2014). Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 13, 673–691. doi: 10.1038/nrd4066

Fan, W., and Luo, J. (2010). SIRT1 regulates UV-induced DNA repair through deacetylating XPA. Mol. Cell 39, 247–258. doi: 10.1016/j.molcel.2010.07.006

Fang, J., Ianni, A., Smolka, C., Vakhrusheva, O., Nolte, H., Kruger, M., et al. (2017). Sirt7 promotes adipogenesis in the mouse by inhibiting autocatalytic activation of SirT1. Proc. Natl. Acad. Sci. U.S.A. 114, E8352–E8361.

Feldman, J. L., Baeza, J., and Denu, J. M. (2019). Epigenetic therapy with panobinostat combined with bicalutamide rechallenges in castration-resistant prostate cancer. Clin. Cancer Res. 25, 52–63. doi: 10.1158/1078-0432.ccr-18-1589

Filippakopoulos, P., and Knapp, S. (2014). Targeting bromodomains: epigenetic readers of lysine acetylation. Nat. Rev. Drug Discov. 13, 337–356. doi: 10.1038/nrd4236

Finley, L. W., Carracedo, A., Lee, J., Souza, A., Egia, A., Zhang, J., et al. (2011). SIRT3 opposes reprogramming of cancer Cell Metabolism through HDAC1 destabilization. Cancer Cell 19, 416–428. doi: 10.1016/j.ccr.2011.02.014
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rikind, R. A., Marks, P. A., et al. (1999). Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401, 188–193. doi: 10.1038/43710
Fischer, D. D., Cai, R., Bhata, U., Asselbergs, F. A., Song, C., Terry, R., et al. (2002). Isolation and characterization of a novel class II histone deacetylase, HDAC10. J. Biol. Chem. 277, 6656–6666. doi: 10.1074/jbc.m1055200
Fiebich, A., Goethals, W., Stuurman, V., Chen, J., Ma, H., Ha, K., Saenz, D. T., et al. (2016). SIRT2 deacetylases and inhibits the peroxisome activity of peroxiredoxin-1 to sensitize breast cancer cells to oxidant stress-inducing agents. Cancer Res. 76, 5467–5478. doi: 10.1158/0008-5472.can-16-0126
Foss, F., Advari, R., Duvic, M., Hymes, K. B., Inagamura, T., Leibakula, A., et al. (2015). A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br. J. Haematol. 168, 811–819. doi: 10.1111/bjh.13222
Fujisawa, T., and Filippakopoulos, P. (2017). Functions of bromodomain-containing proteins and their roles in homeostasis and cancer. Nat. Rev. Mol. Cell Biol. 18, 246–262. doi: 10.1038/nrm.2016.143
Fukumoto, T., Park, P. H., Wu, S., Fatkhitdinov, N., Karaskevich, S., Nacarelli, T., et al. (2018). Repurposing Pan-HDAC inhibitors for ARID1A-mutated ovarian cancer. Cell Rep. 22, 3393–3400. doi: 10.1016/j.celrep.2018.03.019
Funato, K., Hayashi, T., Echizen, K., Negishi, L., Shimizu, N., Koyama-Nasu, R., et al. (2018). SIRT2-mediated inactivation of p73 is required for glioblastoma tumorigenesis. EMBO Rep. 19:e4558.
Fyodorov, D. V., Zhou, B. R., Skoultchi, A. I., and Bai, Y. (2018). Emerging roles of linker histones in regulating chromatin structure and function. Nat. Rev. Mol. Cell Biol. 19, 192–206. doi: 10.1038/nrm.2017.94
Galloway, T. J., Wirth, L. J., Colevas, A. D., Gilbert, J., Bauman, J. E., Saba, N. F., et al. (2015). A Phase I Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin. Cancer Res. 21, 1566–1573. doi: 10.1158/1078-0432-CCR-14-2820
Gammoh, N., Lam, D., Puente, C., Ganley, I., Marks, P. A., and Jiang, X. (2012). Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proc. Natl. Acad. Sci. U.S.A. 109, 6651–6656. doi: 10.1073/pnas.120429109
Gao, C., Hu, C. C., Reineke, E., Lam, M., Cheng, X., Stanya, K. J., et al. (2008). Histone deacetylase 7 promotes PML sumoylation and is essential for PML nuclear body formation. Mol. Cell Biol. 28, 5658–5667. doi: 10.1128/mcb.00874-08
Gao, L., Cueto, M. A., Asselbergs, F., and Atadja, P. (2002). Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 277, 25748–25755. doi: 10.1074/jbc.m111871200
Gao, Y. S., Hubbert, C. C., Lu, J., Lee, Y. S., Lee, J. Y., and Yao, T. P. (2007). Histone deacetylase 6 regulates growth factor-induced actin remodeling and endocytosis. Mol. Cell Biol. 27, 8837–8847. doi: 10.1128/mcb.00393-07
Ginsburg, E., Salomon, D., Sreevalsan, T., and Freese, E. (1973). Growth inhibition of mouse melanoma cells treated with 5-aza-2′-deoxycytidine. Proc. Natl. Acad. Sci. U.S.A. 70, 2457–2461. doi: 10.1073/pnas.70.8.2457
Glozak, M. A., and Seto, E. (2007). Histone deacetylases and cancer. Oncogene 26, 5420–5432.
Goder, A., Emmerich, C., Nikolova, T., Kiweler, N., Schreiber, M., Kuhl, T., et al. (2019). Dual inhibition of PI3K signaling and histone deacetylase halts proliferation and induces lethality in mantle cell lymphoma. Oncogene 38, 1802–1814. doi: 10.1038/s41388-018-0550-3
Guo, L., Zhou, S. R., Wei, X. B., Liu, Y., Chang, X. X., Liu, Y., et al. (2016). Acetylation of mitochondrial trifunctional protein alpha-subunit enhances its stability to promote fatty acid oxidation and is decreased in nonalcoholic fatty liver disease. Mol. Cell. Biol. 36, 2553–2567. doi: 10.1128/mcb.00227-16
Guo, Q., Li, F., Duan, Y., Wen, C., Wang, W., Zhang, L., et al. (2020). Oxidative stress, nutritional antioxidants and beyond. Sci. China Life Sci. 63, 866–874. doi: 10.1007/s11427-019-9591-5
Haberland, M., Johnson, A., Mokalled, M. H., Montgomery, R. L., and Olson, E. N. (2009). Genetic dissection of histone deacetylase requirement in tumor cells. Proc. Natl. Acad. Sci. U.S.A. 106, 7751–7755. doi: 10.1073/pnas.090319109
Hai, Y., and Christianson, D. W. (2016). Histone deacetylase 6 structure and molecular basis of catalysis and inhibition. Nat. Chem. Biol. 12, 741–747. doi: 10.1038/nchembio.2134
Hai, Y., Shinsky, S. A., Porter, N. J., and Christianson, D. W. (2017). Histone deacetylase 10 structure and molecular function as a polyamine deacetylase. Nat. Chem. 9, 15368.
Hajis, M. C., Mostoslavsky, R., Haigis, K. M., Fahie, K., Christodoulou, D. C., Murphy, A. J., et al. (2006). SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell 126, 941–954. doi: 10.1016/j.cell.2006.06.057
Harms, K. L., and Chen, X. (2007). Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res. 67, 3145–3152. doi: 10.1158/0008-5472.can-06-4397
Hassig, C. A., Fleischer, T. C., Billin, A. N., Schreiber, S. L., and Ayer, D. E. (1997). Histone deacetylase activity is required for full transcriptional repression by mSin3A. Cell 89, 341–347. doi: 10.1016/s0009-8674(00)80214-7
Heideman, M. R., Wilking, R. H., Yanover, E., Velds, A., De Jong, I., Kerkhoven, R. M., et al. (2013). Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function. Blood 121, 2038–2050. doi: 10.1182/blood-2012-08-450916
Hershberger, K. A., Abraham, D. M., Liu, J., Locasale, J. W., Grimsrud, P. A., and Hirshey, M. D. (2018). Activation of Sirtuin5 in the postnatal mouse heart results in protein succinylation and normal survival in response to chronic pressure overload. J. Biol. Chem. 293, 10630–10645. doi: 10.1074/jbc.a118.002187
Hideshima, T., Bradner, J. E., Wong, J., Chauhan, D., Richardson, P., Schreiber, S. L., et al. (2005). Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc. Natl. Acad. Sci. U.S.A. 102, 8567–8572. doi: 10.1073/pnas.0503221102
Hideshima, T., Qi, J., Paranal, R. M., Tang, W., Greenberg, E., West, N., et al. (2016). Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proc. Natl. Acad. Sci. U.S.A. 113, 13162–13167. doi: 10.1073/pnas.1608067113

Hirschy, M. D., Shimazu, T., Goetzman, E., Jing, E., Schwer, B., Lombard, D. B., et al. (2010). SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 464, 121–125. doi: 10.1038/nature08778

Ho, M., Chen, T., Liu, J., Dowling, P., Hideshima, T., Zhang, L., et al. (2020). Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating esooles and IL-6 trans-signaling. Leukemia 34, 196–209. doi: 10.1038/s41375-019-0493-x

Hook, S. S., Orian, A., Cowley, S. M., and Eisenman, R. N. (2002). Histone deacetylase 6 binds polyubiquitin through its zinc finger (PAZ) domain and copurifies with deubiquitinating enzymes. Proc. Natl. Acad. Sci. U.S.A. 99, 13425–13430. doi: 10.1073/pnas.172513699

Hou, T., Cao, Z., Zhang, J., Tang, M., Tian, Y., Li, Y., et al. (2020). SIRT6 coordinates with CHD4 to promote chromatin relaxation and DNA repair. Nucleic Acids Res. 48, 2982–3000. doi: 10.1093/nar/gkaa006

Houtkoper, R. H., Pirinen, E., and Auerw, J. (2012). Sirtuins as regulators of metabolism and healthspan. Nat. Rev. Mol. Cell Biol. 13, 225–238. doi: 10.1038/nrm3293

Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., et al. (2003). Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425, 191–196. doi: 10.1038/nature01960

Hsia, D. A., Tepper, C. G., Pochampalli, M. R., Hsia, E. Y., Izumiya, C., Huerta, S. B., et al. (2010). KDM8, a H3K36me2 histone demethylase that acts in the HDAC1/2 complex reveals the structural basis for complex assembly and disease. J. Biol. Chem. 285, 15254–15264. doi: 10.1074/jbc.m007372200

Huang, H., Sabari, B. R., Garcia, B. A., Allis, C. D., and Zhao, Y. (2014). SnapShot: Histone H3K9 acetylation by HDAC1/2 complex regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell 23, 450–463. doi: 10.1016/j.ccr.2013.02.024

Hubbard, B. P., Gomes, A. P., Dai, H., Li, J., Case, A. W., Considine, T., et al. (2013). Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 339, 1216–1219.

Hubbert, C., Guardiola, A., Shao, R., Kawaguishi, Y., Ito, A., Nixon, A., et al. (2002). HDAC6 is a microtubule-associated deacetylase. Nature 417, 455–458. doi: 10.1038/417455a

Hubbi, M. E., Hu, H., Khishit, Gilkes, D. M., and Semenza, G. L. (2013). Sirtuin-7 inhibits the activity of hypoxia-inducible factors. J. Biol. Chem. 288, 20768–20775. doi: 10.1074/jbc.m113.476903

Humphrey, G. W., Wang, Y., Russanova, R. V., Hirai, T., Qin, J., Nakatani, Y., et al. (2001). Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/NAV-007 and Mta-li. J. Biol. Chem. 276, 6817–6824. doi: 10.1074/jbc.m007372200

Igase, M., Fujiki, N., Shubutani, S., Sakai, H., Noguchi, S., Nemoto, Y., et al. (2020). Tenovin-6 induces the SIRT-independent cell growth suppression and blocks autophagy flux in canine hemangiosarcoma cell lines. Exp. Cell Res. 388:111810. doi: 10.1016/j.yexcr.2019.111810

Imai, S., Armstrong, C. M., Kaeberlein, M., and Guarente, L. (2000). Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403, 795–800. doi: 10.1038/3500162

Imai, S., and Guarente, L. (2014). NAD+ and sirtuins in aging and disease. Trends Cell Biol. 24, 464–471. doi: 10.1016/j.tcb.2014.04.002

Ingham, O. J., Paranal, R. M., Smith, W. B., Escobar, R. A., Yueh, H., Snyder, T., et al. (2016). Development of a potent and selective HDAC8 inhibitor. ACS Med. Chem. Lett. 7, 929–932.

Inoue, A., and Fujimoto, D. (1969). Enzymatic deacetylation of histone. Biochem. Biophys. Res. Commun. 36, 145–150. doi: 10.1016/0006-291x(69)90661-5

Itazaki, H., Nagashima, K., Sugita, K., Yoshida, H., Kawamura, Y., Yasuda, Y., et al. (1990). Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having deacetylation activities as antitumor agents. J. Antibiot. 43, 1524–1532. doi: 10.7164/antibiotics.43.1524

Itoh, T., Fairall, L., Musckett, F. W., Milano, C. P., Watson, P. J., Arnaudo, N., et al. (2015). Structural and functional characterization of a cell cycle associated HDAC1/2 complex reveals the structural basis for complex assembly and nucleosome targeting. Nucleic Acids Res. 43, 2033–2044. doi: 10.1093/nar/gkw068

Jackson, S. P., and Bartek, J. (2009). The DNA damage response in human biology and disease. Nature 461, 1071–1078. doi: 10.1038/nature08467

Jamaluddin, S., Kelly, R. D., O’Regan, L., Dovey, O. M., Hodson, G. E., Millard, C. J., et al. (2014). Histone deacetylase (HDAC) 1 and 2 are essential for accurate cell division and the pluripotency of embryonic stem cells. Proc. Natl. Acad. Sci. U.S.A. 111, 9840–9845. doi: 10.1073/pnas.1321330111

Jarrett, S. G., Carter, K. M., Bautista, R. M., He, D., Wang, C., and D’orazio, J. A. (2018). Sirtuin 1-mediated deacetylation of XPA DNA repair protein enhances its interaction with ATR protein and promotes CAMP-induced DNA repair of UV damage. J. Biol. Chem. 293, 19025–19037. doi: 10.1074/jbc.r118.007960

Jedrusik-Bode, M., Studencka, M., Smolka, C., Baumann, T., Schmidt, H., Kampf, J., et al. (2013). The sirtuin SIRT6 regulates stress granule formation in C. elegans and mammals. J. Cell Sci. 126, 5166–5177. doi: 10.1242/jcs.130708

Jenuwein, T., and Allis, C. D. (2001). Translating the histone code. Science 293, 1074–1080. doi: 10.1126/science.1063127

Jeong, S. M., Lee, A., Lee, J., and Haigis, M. C. (2014). SIRT4 protein suppresses tumor formation in genetic models of Myc-induced B cell lymphoma. J. Biol. Chem. 289, 4135–4144. doi: 10.1074/jbc.m113.525949

Jeong, S. M., Xiao, C., Finley, L. W., Lahusen, T., Souza, A. L., Pierce, K., et al. (2013). SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell 23, 450–463. doi: 10.1016/j.ccr.2013.02.024

Ji, H., Zhou, Y., Zhuang, X., Zhu, Y., Wu, Z., Lu, Y., et al. (2019). HDAC3 deficiency promotes liver cancer through a defect in H3K9ac/H3K9me3 transition. Cancer Res. 79, 3676–3688.

Jiang, H., Khan, S., Wang, Y., Charron, G., He, B., Sebastian, C., et al. (2013). SIRT6 regulates TNF-alpha secretion through hydrolysis of long-chain fatty acyl lysine. Nature 496, 110–113. doi: 10.1038/nature12038
Jiang, Y., and Hsieh, J. (2014). HDAC3 controls gap 2/mitosis progression in adult neural stem/progenitor cells by regulating CDK1 levels. Proc. Natl. Acad. Sci. U.S.A. 111, 13541–13546. doi: 10.1073/pnas.1411959111

Jiang, Z., Li, W., Hu, X., Zhang, Q., Sun, T., Cui, S., et al. (2019). Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor–positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 806–815. doi: 10.1016/s1470-2045(19)30164-0

Jin, X., Yan, Y., Wang, D., Ding, M., Ma, T., Ye, Z., et al. (2018). DUB3 Promotes BET inhibitor resistance and cancer progression by deubiquitinating BRD4. Mol. Cell 71, 592–605.e4.

Jing, H., Hu, J., He, B., Negron Abril, Y. L., Stupinski, J., Weiser, K., et al. (2016). A SIRT2-selective inhibitor promotes c-Myc oncprotein degradation and exhibits broad anticancer activity. Cancer Cell 29, 297–310. doi: 10.1016/j.ccc.2016.02.007

Jones, P. A., Isa, J. P., and Baylin, S. (2016). Targeting the cancer epigenome for therapy. Nat. Rev. Genet. 17, 630–641.

Kim, J. E., Chen, J., and Lou, Z. (2008). DBC1 is a negative regulator of SIRT1. Nature 451, 583–586. doi: 10.1038/nature06500

Kim, J. H., Kim, D., Cho, S. J., Jung, K. Y., Kim, J. H., Lee, J. M., et al. (2019). Identification of a novel SIRT7 inhibitor as anticancer drug candidate. Biochem. Biophys. Res. Commun. 508, 451–457. doi: 10.1016/j.bbrc.2018.11.120

Kim, J. J., Lee, Y. S., and Miller, K. M. (2019). Preserving genome integrity and function: the DNA damage response and histone modifications. Crit. Rev. Biochem. Mol. Biol. 54, 208–241. doi: 10.1080/10409238.2019.1620676

Kim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., et al. (2014). Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl. Acad. Sci. U.S.A. 111, 11774–11779. doi: 10.1073/pnas.1410626111

Kim, K. K., Shapprod, and Chapman, H. A. (2018). TGF-beta1 signaling and tissue fibrosis. Cold Spring Harb. Perspect. Biol. 10:a022293.

Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J. E., Lee, S. W., et al. (2001). Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 7, 437–443. doi: 10.1038/56507

Kim, Y. H., Bagot, M., Pinter-Brown, L., Rook, A. H., Porcu, P., Horwitz, S. M., et al. (2018). Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 19, 1192–1204.

Kiran, S., Chatterjee, N., Singh, S., Kaul, S. C., Wadhwa, R., and Ramakrishna, G. (2013). Intracellular distribution of human SIRT7 and mapping of the nuclear/nucleolar localization signal. FEBS J. 280, 3451–3466. doi: 10.1111/febs.12346

Kosciuczuk, E. M., Mehrotra, S., Saleiro, D., Kozyczynska, B., Majchrzak-Kita, B., Lisowski, P., et al. (2019). Sirtuin 2-mediated deacetylation of cyclin-dependent kinase 9 promotes STAT1 signaling in type I interferon responses. J. Biol. Chem. 294, 827–837. doi: 10.1074/jbc.RA118.005956

Ko, H. S., Patel, K., Muldoon-Jacobs, K., Bisht, K. S., Aiykin-Burns, N., Poling, J. D., et al. (2010). SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 17, 41–52. doi: 10.1016/j.ccc.2009.11.023

Ko, H. S., Vassilopoulos, A., Wang, R. H., LahuSen, T., Xiao, X., Xu, X., et al. (2011). SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell 20, 487–499. doi: 10.1016/j.ccr.2011.09.004

Kolar, Z., Mikesova, J., Zessin, M., Meleshin, M., Novakova, Z., Alquicer, G., et al. (2018). Suppression of TGFbeta-mediated conversion of endothelial cells who have progressed on previous chemotherapy (V ANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 16, 447–456.

Kugel, S., Sebastian, C., Fitamant, J., Ross, K. N., Saha, S. K., Jain, E., et al. (2016). SIRT6 suppresses pancreatic cancer through control of Lin28b. Cell 165, 1401–1415. doi: 10.1016/j.cell.2016.04.033

Kutateladze, T. G. (2011). Histone Deacetylase 11 Is a Fatty-Acid Deacylase. ACS Chem. Biol. 6, 19895–19904. doi: 10.1021/acschembio.9b02808

Kutateladze, T. G., Macek, Z., Novakova, Z., Meleshin, M., Kohout, P., and Kutateladze, T. G. (2011). Histone Deacetylase 11 Is a Fatty-Acid Deacylase. ACS Chem. Biol. 6, 19895–19904. doi: 10.1021/acschembio.9b02808

Kutateladze, T. G., Macek, Z., Novakova, Z., Meleshin, M., Kohout, P., and Kutateladze, T. G. (2011). Histone Deacetylase 11 Is a Fatty-Acid Deacylase. ACS Chem. Biol. 6, 19895–19904. doi: 10.1021/acschembio.9b02808

Kutateladze, T. G., Macek, Z., Novakova, Z., Meleshin, M., Kohout, P., and Kutateladze, T. G. (2011). Histone Deacetylase 11 Is a Fatty-Acid Deacylase. ACS Chem. Biol. 6, 19895–19904. doi: 10.1021/acschembio.9b02808

Kutateladze, T. G., Macek, Z., Novakova, Z., Meleshin, M., Kohout, P., and Kutateladze, T. G. (2011). Histone Deacetylase 11 Is a Fatty-Acid Deacylase. ACS Chem. Biol. 6, 19895–19904. doi: 10.1021/acschembio.9b02808

Kutateladze, T. G., Macek, Z., Novakova, Z., Meleshin, M., Kohout, P., and Kutateladze, T. G. (2011). Histone Deacetylase 11 Is a Fatty-Acid Deacylase. ACS Chem. Biol. 6, 19895–19904. doi: 10.1021/acschembio.9b02808
Lim, B., Murthy, R. K., Lee, J., Jackson, S. A., Iwase, T., Davis, D. W., et al. (2019). A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. Br. J. Cancer 120, 1105–1112. doi: 10.1038/s41416-019-0473-y

Lim, J. H., Lee, Y. M., Chun, Y. S., Chen, J., Kim, J. E., and Park, J. W. (2010). Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Mol. Cell. Biol. 30, 384–394. doi: 10.1128/mcb.01800-13

Lin, C. L., Tsai, M. L., Lin, C. Y., Hsu, K. W., Hsieh, W. S., Chi, W. M., et al. (2019). HDAC1 and HDAC2 double knockout triggers cell apoptosis in advanced thyroid cancer. Int. J. Mol. Sci. 20:454. doi: 10.3390/ijms20020454

Lin, S. J., Defossez, P. A., and Guarente, L. (2000). Requirement of NAD and SIRT2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science 289, 2116–2126. doi: 10.1126/science.289.5487.2126

Liszczak, G., Diehl, K. L., Dann, G. F., and Muir, T. W. (2018). Acetylation blocks DNA damage-induced chromatin ADP-ribosylation. Nat. Chem. Biol. 14, 837–840. doi: 10.1038/nchembio.2709

Liu, G., Bi, Y., Shen, B., Yang, H., Zhang, Y., Wang, X., et al. (2014). SIRT1 limits the function and fate of myoid-derived suppressor cells in tumors by orchestrating HIF-1alpha-dependent glycolysis. Cancer Res. 74, 727–737. doi: 10.1158/0008-5472.can-13-2584

Liu, P. Y., Xu, N., Malylukova, A., Scarlett, C. J., Sun, Y. T., Zhang, X. D., et al. (2013). The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death Differ. 20, 503–514. doi: 10.1038/cdd.2012.147

Liu, T., Lee, A. E., Porro, A., Smith, S. A., Darte, T., Liu, P. Y., et al. (2007). Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. Proc. Natl. Acad. Sci. U.S.A. 104, 16862–16867. doi: 10.1073/pnas.0705521104

Liu, X., Wang, D., Zhao, Y., Tu, B., Zheng, Z., Wang, L., et al. (2011). Methytransferase Srt7/9 regulates p53 activity by interacting with Sirtuin 1 (SIRT1). Proc. Natl. Acad. Sci. U.S.A. 108, 1925–1930. doi: 10.1073/pnas.1019619108

Liu, Y., Peng, L., Seto, E., Huang, S., and Quy, Y. (2012). Modulation of histone deacetylase 6 (HDAC6) nuclear import and tubulin deacetylase activity through acetylation. J. Biol. Chem. 287, 29168–29174. doi: 10.1074/jbc.M112.371120

Lombard, D. B., Allen, F. W., Cheng, H. L., Banenkorth, J., Streep, R. R., Mostoslavsky, R., et al. (2007). Mammalian Srt2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol. Cell. Biol. 27, 8807–8814. doi: 10.1128/mcb.01636-07

Luo, J., and Holmgren, A. (2014). The thioredoxin antioxidant system. Free Radic. Biol. Med. 66, 75–87. doi: 10.1016/j.freeradbiomed.2013.07.036

Luo, X., Tang, M., Zhu, Q., Yang, Q., Li, Z., Bao, Y., et al. (2019). GLP-catalyzed H4K16me1 promotes 3BP1 recruitment to permit DNA damage repair and cell survival. Nucleic Acids Res. 47, 10977–10993. doi: 10.1093/nar/gkx897

Luo, X. F., Cao, X. Y., Zhu, Y. J., Wu, Z. R., Zhuang, X., Shao, M. Y., et al. (2018). Histone deacetylase 3 promotes liver regeneration and liver cancer cells proliferation through signal transducer and activator of transcription 3 signaling pathway. Cell Death Dis. 9:398.

Luo, Y., Stuart, J. H., Talbot-Cooper, C., Agrawal-Singh, S., Huntly, B., Smid, A. I., et al. (2019). Histone deacetylase 4 promotes type I interferon signaling, restricts tumor growth, and regulates global mitochondrial lysine acetylation. Mol. Cell. Biol. 27, 8807–8814. doi: 10.1128/mcb.01636-07
of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. *Autophagy* 10, 1403–1414. doi: 10.4161/auto.29231

Mani, S. A., Guo, W., Liao, M. J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell* 133, 704–715.

Mao, R., Wu, Y., Ming, Y., Xu, Y., Wang, S., Chen, X., et al. (2019). Enhancer RNAs: a missing regulatory layer in gene transcription. *Sci. China Life Sci.* 62, 905–912. doi: 10.1007/s11427-017-9370-9

Mao, Z., Hine, C., Tian, X., Van Meter, M., Au, M., Vaidya, A., et al. (2011). SIRT6 promotes DNA repair under stress by activating PARP1. *Science* 332, 1443–1446. doi: 10.1126/science.1207233

Marquardt, J. U., Fischer, K., Baus, K., Kashyap, A., Ma, S., Krupp, M., et al. (2013). Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. *Hepatology* 58, 1054–1064. doi: 10.1002/hep.26413

Martin, M. W., Lee, J. Y., Lancia, D. R. Jr., Ng, P. Y., Han, B., Thomason, J. R., et al. (2018). Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11. *Biosig. Med. Chem. Lett.* 28, 2143–2147. doi: 10.1016/j.bmcl.2018.05.021

Mathias, R. A., Greco, T. M., Oberstein, A., Budayeva, H. G., Chakrabarti, R., Rowland, E. A., et al. (2014). Sirtuin 4 is a lipoamide dehydrogenase regulating pyruvate dehydrogenase complex activity. *Cell* 159, 1615–1625. doi: 10.1016/j.cell.2014.11.046

Mazur, P. K., Herter, A., Mello, S. S., Wirth, M., Hausmann, S., Sanchez-Rivera, F. J., et al. (2015). Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. *Nat. Med.* 21, 1163–1171. doi: 10.1038/nm.3952

Mckinsey, T. A., Kuwahara, K., Berezovzannaya, S., and Olson, E. N. (2006). Class II histone deacetylases confer signal responsiveness to the ankyrin-repeat proteins ANKRA2 and RXFANK. *Mol. Biol. Cell* 17, 438–447. doi: 10.1091/mbc.e05-07-0612

Mckinsey, T. A., Zhang, C. L., Lu, J., and Olson, E. N. (2000). Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. *Nature* 408, 106–111. doi: 10.1038/35040593

Mckinsey, T. A., Zhang, C. L., and Olson, E. N. (2001). Identification of a signal-responsive nuclear export sequence in class II histone deacetylases. *Mol. Cell. Biol.* 21, 6312–6321. doi: 10.1128/mcb.21.18.6312–6321.2001

Medina, V., Edmonds, B., Young, G. P., James, R., Appleton, S., and Zalewski, P. D. (1997). Induction of caspase-3 protease activity and apoptosis by butyrate dehydrogenase complex activity. *Cell* 159, 1615–1625. doi: 10.1016/j.cell.2014.11.046

Melo, C. A., Drost, J., Wijchers, P. J., Van De Werken, H., De Wit, E., Oude Vrielink, J. A., et al. (2013). Class I HDACs share a common mechanism of regulation by inositol phosphates. *Nat. Cell Biol.* 15, 704–715. doi: 10.1038/ncb2646

Mizushima, N. (2018). A brief history of autophagy from cell biology to physiology. *Nat. Rev. Mol. Cell Biol.* 19, 524–535. doi: 10.1038/s41556-018-0092-5

Mizushima, N., Levine, B., Cuervo, A. M., and Klionsky, D. J. (2008). Autophagy fights disease through cellular self-digestion. *Nature* 451, 1069–1070. doi: 10.1038/nature06639

Mohrin, M., Shin, J., Liu, Y., Brown, K., Luo, H., Xi, Y., et al. (2015). Stem cell aging. A mitochondrial UPR-mediated metabolic checkpoint regulates hematopoietic stem cell aging. *Science* 347, 1374–1377. doi: 10.1126/science.aaa2361

Monte, M., Simonatto, M., Peche, L. Y., Bublik, D. R., Gobessi, S., Pierotti, M. A., et al. (2006). MAG6-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. *Proc. Natl. Acad. Sci. U.S.A.* 103, 11160–11165. doi: 10.1073/pnas.0510384310

Montgomery, R. L., Davis, C. A., Potthoff, M. J., Haberland, M., Fieltz, J., Qi, X., et al. (2007). Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. *Genes Dev.* 21, 1790–1802. doi: 10.1101/gad.1563807

Moon, H., Zhu, J., and White, A. C. (2019). Sirt5 is dispensable for Braf(V600E)-mediated cutaneous melanoma development and growth in vivo. *Exp. Dermatol.* 28, 83–85. doi: 10.1111/exd.13845

Moresi, V., Carrer, M., Grueter, C. E., Rifki, O. F., Shelton, J. M., Richardson, J. A., et al. (2012). Histone deacetylases 1 and 2 regulate autophagy flux and skeletal muscle homeostasis in mice. *Proc. Natl. Acad. Sci. U.S.A.* 109, 1649–1654. doi: 10.1073/pnas.1121591901

Moresi, V., Williams, A. H., Meadows, E., Flynn, J. M., Potthoff, M. J., Mcanally, J., et al. (2010). Myogenin and class II HDACs control neurogenic muscle atrophy and soft tissue sarcoma growth. *Cancer Res.* 70, 7035–7041. doi: 10.1158/0008-5472.can-10-2597

Nakazawa, M. S., Eisinger-Mathason, T. S., Sadri, N., Ochocki, J. D., Gade, T. P., and Kutateladze, T. G. (2012). Perceiving the epigenetic landscape through histone readers. *Nat. Struct. Mol. Biol.* 19, 1218–1227. doi: 10.1038/nsmb.2436

Nagy, L., Kao, H. Y., Chakravarti, D., Lin, R. J., Hassig, C. A., Ayer, D. E., et al. (2013). Human HDAC1 and HDAC2 function in the DNA-damage response of human stem cells. *Nat. Cell Biol.* 15, 704–715. doi: 10.1038/ncb2646
Nebbioso, A., Carafa, V., Conte, M., Tambaro, F. P., Abbondanza, C., Martens, J., et al. (2017). c-Myc Modulation and Acetylation Is a Key HDAC inhibitor target in cancer. *Clin. Cancer Res.*, 23, 2542–2555. doi: 10.1158/1078-0432-ccr-15-2388

Newbold, A., Jordan, J. M., Martin, B. P., Stanley, K., and Johnstone, R. W. (2014). The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Emsi-myc model of B-cell lymphoma. *Oncogene* 33, 5415–5423. doi: 10.1038/onc.2013.482

Newkirk, T. L., Bowers, A. A., and Williams, R. M. (2009). Discovery, biological activity, synthesis and potential therapeutic utility of naturally occurring histone deacetylase inhibitors. *Nat. Prod. Rep.*, 26, 1293–1320. doi: 10.1039/b81788k

Ng, H. H., Zhang, Y., Hendrich, B., Johnson, C. A., Turner, B. M., Erdjument-Bromage, H., et al. (1999). MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. *Nat. Genet.*, 23, 58–61. doi: 10.1038/12659

Ng, R., and Huen, M. S. Y. (2020). Deacetylation of a deacetylase drives the DNA damage response. *Genome Instab. Dis.*, 1, 151–154. doi: 10.1038/s42764-020-00018-7

Nguyen, P., Lee, S., Lorang-Leins, D., Trepel, J., and Smart, D. K. (2014). SIRT2 interacts with beta-catenin to inhibit Wnt signaling output in response to radiation-induced stress. *Mol. Cancer Res.*, 12, 1244–1253. doi: 10.1158/1541-7786.mcr-14-0223-1

Nguyen, P., Shukla, S., Liu, R., Abbineni, G., and Smart, D. K. (2019). Sirt2 regulates radiation-induced injury. *Radiat. Res.*, 191, 398–412. doi: 10.1667/rr15282.1

Nicholson, J., Jeon, S. J., Grosse, B., Ellermann, S., Konietzky, R., Kers, M., et al. (2017). E3 Ligase cIAP2 Mediates Downregulation of MRE11 and Radioresensation in Response to HDAC Inhibition in Bladder Cancer. *Cancer Res.*, 77, 3027–3039. doi: 10.1158/0008-5472.can-16-3322

Ning, Y., Ding, J., Sun, X., Xie, Y., Su, M., Ma, C., et al. (2020). HDAC9 deficiency promotes tumor progression by decreasing the CD8(+) dendritic cell infiltration of the tumor microenvironment. *J. Immunother.* 8(4):000529. doi: 10.1136/jitc-2020-000529

Nishibuchi, G., Shibata, Y., Hayakawa, T., Hayakawa, N., Ohtani, Y., Simmyozu, K., et al. (2014). Physical and functional interactions between the histone H3K4 demethylase KDM5A and the nucleosome remodeling and deacetylase (NuRD) complex. *J. Biol. Chem.*, 289, 28956–28970. doi: 10.1074/jbc.m114.573725

Nishimori, S., Lai, F., Shiraishi, M., Kobayashi, T., Kozhemyakina, E., Yao, T. P., et al. (2019). PTPHR targets HDAC4 and HDAC5 to repress cardiomyocyte hypertrophy. *J. Cell Biol.* 207:97903.

Norrworsy, K. J., Cho, E., Arora, J., Kowalski, J., Tsai, H. L., Warlick, E., et al. (2016). Differentiation therapy in poor risk myeloid malignancies: results of companion phase II studies. *Leuk. Res.*, 49, 90–97. doi: 10.1016/j.leukres.2016.09.003

North, B. J., Marshall, B. L., Borra, M. T., Denu, J. M., and Verdin, E. (2003). The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. *Mol. Cell.*, 11, 437–444. doi: 10.1016/s1097-2765(03)00038-8

Nott, A., Watson, P. M., Robinson, J. D., Crepaldi, L., and Riccio, A. (2008). S-Nitrosylation of histone deacetylase 2 induces chromatin remodelling in human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. *Proc. Natl. Acad. Sci. U.S.A.*, 105, 15090–15095. doi: 10.1073/pnas.1610270114

Pili, R., Quinn, D. I., Hammers, H. J., Monk, P., George, S., Dorrfl, T. R., et al. (2017). Immunomodulation by entinostat in renal cell carcinoma patients receiving high-dose interleukin 2: a multicenter, single-Arm, Phase I/II Trial (NCI-CTEP#87870). *Clin. Cancer Res.*, 23, 7199–7208. doi: 10.1158/1078-0432-ccr-17-1178

Plie, P. G., Tang, C., Mills, G. B., and Yap, T. A. (2019). State-of-the-art strategies for targeting the DNA damage response in cancer. *Nat. Rev. Clonol. Oncol.*, 16, 81–104. doi: 10.1038/s41571-018-0114-2

Popat, R., Brown, R. S., Flanagan, L., Hall, A., Gregory, W., Kishore, B., et al. (2016). Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. *Lancet Haematol.*, 3, e572–e580.

Potente, M., Ghaeni, L., Baldessari, D., Mostoslavsky, R., Rossig, L., Dequidt, F., et al. (2007). SIRT1 controls endothelial angiogenic functions during vascular growth. *Genes Dev.*, 21, 2644–2658. doi: 10.1101/gad.435107

Pouget, J. P., Georgakilas, A. G., and Ravatn, J. L. (2018). Targeted and off-target (bystander and abscopal) effects of radiation therapy: redox mechanisms and risk/benefit analysis. *Antioxid. Redox Signal.* 29, 1447–1487. doi: 10.1089/ars.2017.7287

Pregelj, T., Hammingter, P., Luu, M., Bulat, T., Andersen, L., Gosch, L., et al. (2020). Histone deacetylases 1 and 2 restrain CD4+ cytotoxic T lymphocyte differentiation. *J. Immunother.* 5:e133393.

Puvvada, S. D., Guillen-Rodrigo, J. M., Rivera, X. L., Heard, K., Inclan, L., Schmelz, M., et al. (2017). A Phase II exploration study of PXD-101 (Belinostat) followed by zevalin in patients with relapsed aggressive high-risk lymphoma. J. Oncology 93, 401–405.

Qi, H., Shi, X., Yu, M., Liu, B., Liu, M., Song, S., et al. (2018). Sirtuin 7-mediated deacetylation of WD repeat domain 3 (WDR77) suppresses cancer cell growth by reducing WDR77/PRTM5 transmembrane complex activity. *J. Biol. Chem.*, 293, 17769–17779. doi: 10.1074/jbc.r18003629

Qi, J., Singh, S., Hua, W. K., Cai, Q., Chao, S. W., Li, L., et al. (2015). HDAC8 inhibition specifically targets INV16 acute myeloid leukemic stem cells by
restoring p53 acetylation. Cell Stem Cell 17, 597–610. doi: 10.1016/j.stem.2015.08.004
Qian, D. Z., Kachhap, S. K., Collis, S. J., Verheul, H. M., Carducci, M. A., Atadja, P., et al. (2008). Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res. 68, 8814–8821. doi: 10.1158/0008-5472.can-05-4598
Radhakrishnan, R., Li, Y., Xiang, S., Yuan, F., Yuan, Z., Telles, E., et al. (2015). Histone deacetylase 10 regulates DNA mismatch repair and may involve the deacetylation of MutS homolog 2. J. Biol. Chem. 290, 22795–22804. doi: 10.1074/jbc.m114.612945
Ramsey, M. R., He, L., Forster, N., Ory, B., and Ellenis, L. W. (2011). Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma. Cancer Res. 71, 4573–4579. doi: 10.1158/0008-5472.can-11-0046
Resh, M. D. (2006). Trafficking and signaling by fatty-acylated and prenylated proteins. Nat. Chem. Biol. 2, 584–590. doi: 10.1038/nchembio834
Rezaazadeh, S., Yang, D., Biashad, S. A., Firsanov, D., Takasugi, M., Gilbert, M., et al. (2020). SIRT6 mono-ADP ribosylates KDM2A to locally increase H3K36me2 at DNA damage sites to inhibit transcription and promote repair. Aging 12, 11165–11184. doi: 10.18632/aging.103567
Rezaazadeh, S., Yang, D., Tombline, G., Simon, M., Regan, S. P., Seluanov, A., et al. (2019). SIRT6 promotes transcription of a subset of NRF2 targets by mono-ADP-ribosylation RAF170. Nucleic Acids Res. 47, 7914–7928. doi: 10.1093/nar/gkz528
Richon, V. M., Sandhoff, T. W., Rifkind, R. A., and Marks, P. A. (2000). Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. U.S.A. 97, 10014–10019. doi: 10.1073/pnas.1803161977
Riggs, M. G., Whittaker, R. G., Neumann, J. R., and Ingram, V. M. (1977). n-Dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, double-blind study of a new chemotherapeutic agent in the treatment of advanced breast cancer. Br. J. Cancer 35, 25, 269–277. doi: 10.1038/77023
Santos-Barriopedro, I., Bosch-Peregrue, L., Marazuela-Duque, A., De La Torre, C., Colomer, C., Vazquez, B. N., et al. (2018). SIRT6-dependent cysteine monoubiquitination in the PRE-SET domain of Suv39h1 regulates the NKF-κB pathway. Nat. Commun. 9:101.
Scher, M. R., Vaquero, A., and Reinberg, D. (2007). Sir3T3 is a nuclear NAD+-dependent histone deacetylase that translocates to the mitochondria upon cellular stress. Genes Dev. 21, 920–928. doi: 10.1101/gad.1527307
Schlicker, C., Gertz, M., Papaetereodourou, P., Kachholz, B., Becker, C. F., and Steegborn, C. (2008). Substrates and regulation mechanisms for the human mitochondrial sirtuins Sir3t and Sir5t. J. Mol. Biol. 382, 790–801. doi: 10.1016/j.jmb.2008.07.048
Scholz, C., Weintert, B. T., Wagner, S. A., Beli, P., Miyake, Y., Qi, J., et al. (2015). Acetylation site specificities of lysine deacetylase inhibitors in human cells. Nat. Biotechnol. 33, 415–423. doi: 10.1038/nbt.3130
Schreiber, V., Dantzer, F., Am, J. C., and De Murcia, G. (2006). Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 7, 517–528. doi: 10.1038/nrm1963
Schwer, B., North, B. J., Frye, R. A., Ott, M., and Verdin, E. (2002). The human silent information regulator (Sir)2 homologue hSir3T3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J. Cell Biol. 158, 647–657. doi: 10.1083/jcb.200205057
Scully, R., Panday, A., Elango, R., and Willis, N. A. (2019). DNA double-strand break repair-pathway choice in somatic mammalian cells. Nat. Rev. Mol. Cell Biol. 20, 698–714. doi: 10.1038/s41580-019-0152-0
Sebastian, C., Zwaans, B. M., Silberman, D. M., Gynrek, M., Goren, A., Zhong, L., et al. (2012). The histone deacetylase SirT6 is a tumor suppressor that controls cancer metabolism. Cell 151, 1185–1199. doi: 10.1016/j.cell.2012.10.047
Seto, E., and Yoshida, M. (2014). Erasers of histone acetylation: the HDACs. Nat. Rev. Cancer 14, 689–700. doi: 10.1038/nrc3752
Sen, N., Kumar, R., Singh, M. L., and Das, S. (2013). HDAC5, a key component in temporal regulation of p53-mediated transactivation in response to genotoxic stress. Mol. Cell 52, 406–420. doi: 10.1016/j.molcel.2013.09.003
Senft, D., Qi, J. and Ronai, Z. A. (2018). Ubiquitin ligases in oncogenic transformation and cancer therapy. Nat. Rev. Cancer 18, 68–88. doi: 10.1038/nr.2017.105
Serrano, L., Martinez-Redondo, P., Marazuela-Duque, A., Vazquez, B. N., Dooley, S. J., Voigt, P., et al. (2013). The tumor suppressor Sirt2 regulates cell cycle progression and genome stability by modulating the mitotic deposition of H4K20 methylation. Genes Dev. 27, 639–653. doi: 10.1101/gad.213422.112
Seto, E., and Yoshida, M. (2014). Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb. Perspect. Biol. 6, a018713. doi: 10.1101/cesp.a018713
Shan, B., Yao, T. P., Nguyen, H. T., Zhuo, Y., Levy, D. R., Klingberg, R. C., et al. (2008). Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition. J. Biol. Chem. 283, 21065–21073. doi: 10.1074/jbc.m80276200
Shankaranarayana, G. D., Motamedi, M. R., Moazed, D., and Grewal, S. I. (2003). HDAC5, a key component in oncogenic super-enhancers. Nucleic Acids Res. 31, 1240–1246. doi: 10.1093/nar/gkg049
Shaw, E., Talwadekar, M., Rashida, Z., Mohan, N., Acharya, A., Khatri, S., et al. (2020). Anabolic SIRT4 exerts retrograde control over torc1 signaling by glutamine sparing in the mitochondria. Mol. Cell Biol. 40, e00212-19. doi: 10.1128/MCB.2018.07137
Shechter, D., Dormann, H. L., Allis, C. D., and Hake, S. B. (2007). Extraction, purification and analysis of histones. Nat. Protoc. 2, 1445–1457. doi: 10.1038/nprot.2007.202
Shi, K., Yin, X., Cai, M. C., Yan, Y., Jia, C., Ma, P., et al. (2019). PAX8 regulon in human ovarian cancer links lineage dependency with epigenetic vulnerability to HDAC inhibitors. elife 8:e44306.
Shi, Y., Dong, M., Hong, X., Zhang, W., Feng, J., Zhu, J., et al. (2015). Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann. Oncol. 26, 1766–1771. doi: 10.1093/annonc/mdv237.
Shi, Y. I., Matson, C., Fan, L., Iwase, S., Baba, T., and Shi, Y. (2005). Regulation of LSD1 histone demethylase activity by its associated factors. Mol. Cell 19, 857–864. doi: 10.1016/j.molcel.2005.08.027
Shinsky, S. and Christianson, D. W. (2018). Polyamine deacetylase structure and catalysis: prokaryotic acetylpolymamine amidohydrolase and eukaryotic HDAC10. Biochemistry 57, 3105–3114. doi: 10.1021/acs.biochem.8b00079

Shogren-Knaak, M., Ishii, H., Sun, J. M., Pajon, M. J., Davie, J. R., and Peterson, C. L. (2006). Histone H4-K16 acetylation controls chromatinn structure and protein interactions. Science 311, 844–847. doi: 10.1126/science.1124000

Simon, M., Van Meter, M., Abela, J., Ke, Z., Gonzalez, R. S., Taguchi, T., et al. (2019). LINE1 Derepression in Aged Wild-Type and SIRT6-deficient mice drives inflammation. Cell Metab. 29, 871–885.e5

Sinclair, D. A. and Guarente, L. (2014). Small-molecule allosteric activators of sirtuins. Annu. Rev. Pharmacol. Toxicol. 54, 363–380. doi: 10.1146/annurev-pharmtox-010611-134657

Singh, A. K., Bishayee, A., and Pandey, A. K. (2018). Targeting histone deacetylases with natural and synthetic agents: an emerging anticancer strategy. Nutrients 10:731. doi: 10.3390/nu10060731

Singh, R., Letai, A., and Sarosiek, K. (2019). Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat. Rev. Mol. Cell Biol. 20, 175–193. doi: 10.1038/s41580-018-0089-8

Somoz, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., et al. (2004). Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 12, 1325–1334. doi: 10.1016/j.str.2004.04.012

Son, S. I., Cao, J., Zhu, C. L., Miller, S. P., and Lin, H. (2019). Activity-Guided SIRT1 inhibitor, MHY2245, induces autophagy and inhibits energy metabolism in SKOV3 cells. Cell Metab. 31, 41–45. doi: 10.1016/j.cmet.2019.01.031

Tang, S., Fang, Y., Huang, G., Xu, X., Padilla-Banks, E., Fan, W., et al. (2017). Methionine metabolism is essential for SIRT1-mediated regulated mouse embryonic stem cell maintenance and embryonic development. EMBO J. 36, 3175–3193. doi: 10.15252/embj.201796708

Tang, S., Huang, G., Fan, W., Chen, Y., Ward, J. M., Xu, et al. (2014). SIRT1-mediated deacetylation of CRABPII regulates cellular retinoic acid signaling and modulates embryonic stem cell differentiation. Mol. Cell 55, 843–855. doi: 10.1016/j.molcel.2014.07.011

Tang, X., Li, G., Su, F., Cai, Y., Shi, L., Meng, Y., et al. (2020). HDAC8 cooperates with SMAD3/4 complex to suppress SIRT7 and promote cell survival and migration. Nucleic Acids Res. 48, 2912–2923. doi: 10.1093/nar/gkaa039

Tang, X., Shi, L., Xie, N., Liu, Z., Qian, M., Meng, F., et al. (2017). SIRT7 antagonizes TGF-beta signaling and inhibits breast cancer metastasis. Nat. Commun. 8:318.

Tanno, M., Sakamoto, J., Miura, T., Shimamoto, K., and Horio, Y. (2007). Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J. Biol. Chem. 282, 6823–6832. doi: 10.1074/jbc.m60954200

Tanny, J. C., Dowd, G. I., Huang, J., Hilz, H., and Moazed, D. (1999). An enzymatic activity in the yeast Sir2 protein that is essential for gene silencing. Cell 99, 735–745. doi: 10.1016/S0092-8674(00)81671-2

Taunton, J., Hassig, C. A., and Schreiber, S. L. (1996). A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272, 408–411. doi: 10.1126/science.272.5260.408

Taverna, S. D., Li, H., Rutenberg, A. J., Allis, C. D., and Patel, D. J. (2007). How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat. Struct. Mol. Biol. 14, 1025–1034. doi: 10.1038/nsm1338

Tessarz, P., and Kouzarides, T. (2014). Histone core modifications regulating nucleosome structure and dynamics. Nat. Rev. Mol. Cell Biol. 15, 703–708. doi: 10.1038/nrm3890

Tian, J. L., and Qin, H. (2019). O-GlcNAcylation regulates primary ciliary length by promoting microtubule disassemble. Science 12, 379–391. doi: 10.1126/sci.2019.01.031

Tian, X., Firsanov, D., Zhang, Z., Cheng, Y., Luo, L., Tombine, G., et al. (2019). SIRT6 is responsible for more efficient DNA double-strand-break repair in long-lived species. Cell 177, 622–638.e22

Tian, Y., Wong, W. V., Wong, G. L., Yang, W., Sun, H., Shen, J., et al. (2015). Histone Deacetylase 9 promotes insulin resistance and beta-catenin activation in NAFLD-associated hepatocellular carcinoma. Cancer Res. 75, 4803–4816. doi: 10.1158/0008-5472.can-14-3786

Toiber, D., Erdel, F., Bouazoune, K., Silberman, D. M., Zhong, L., Mulligan, P., et al. (2013). SIRT6 recruits SNF2H to DNA break sites, preventing genomic instability through chromatin remodeling. Mol. Cell 51, 454–468. doi: 10.1016/j.molcel.2013.06.018

Tong, J., Zheng, X., Tan, X., Fletcher, R., Nikolovska-Coleska, Z., Yu, J., et al. (2018). Mc1r phosphorylation without degradation mediates sensitivity to HDAC inhibitors by liberating BH3-only proteins. Cancer Res. 78, 4704–4715. doi: 10.1158/0008-5472.can-18-0399

Tong, J., Liu, J., Bertos, N. R., and Yang, X. J. (2002). Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain. Nucleic Acids Res. 30, 1114–1123. doi: 10.1093/nar.30.5.1114

Topper, M. J., Vaz, M., Chiappinelli, K. B., Destefano Shields, C. E., Niknafs, N., et al. (2018). Mitochondrial Deacetylase SIRT3 plays an important role in donor T cell responses after experimental allogeneic hematopoietic transplantation. J. Immunol. 201, 3443–3455. doi: 10.4049/jimmunol.1801484

Tsuji, N., Kobayashi, M., Nagashima, K., Wakisaka, Y., and Koizumi, K. (1976). A new antifungal antibiotic, trichostatin. J. Antibiot. 29, 1–6. doi: 10.7164/antibiotics.29.1

Turnbull, R. E., Fairall, L., Saleh, A., Kelsall, E., Morris, K. L., Ragan, T. J., et al. (2020). The MiDAC histone deacetylase complex is essential for embryonic development and has a unique multivalent structure. Nat. Commun. 11:3252

Urinsova, K., Novakova, Z., Saito, M., Melehin, M., Mikesova, J., Kutil, Z., et al. (2020). The disordered N-terminus of HDAC6 is a microtubule-binding domain critical for efficient tubulin deacetylation. J. Biol. Chem. 295, 2614–2628. doi: 10.1074/jbc.r119.011243
Van Der Vlag, J., and Otte, A. P. (1999). Transcriptional repression mediated by Wang, A. H., Kruhlak, M. J., Wu, J., Bertos, N. R., Vezmar, M., Posner, B. I., et al. (2000). Regulation of histone deacetylation 4 by binding of 14-3-3 proteins. Mol. Cell. Biol. 20, 6904–6912. doi: 10.1128/mcb.20.18.6904-6912.2000

Wang, A. H., and Yang, X. J. (2001). Histone deacetylase 4 possesses intrinsic nuclear import and export signals. Mol. Cell. Biol. 21, 5992–6005. doi: 10.1128/mcb.21.17.5992-6005.2001

Wang, B., Rao, Y. H., Inoue, M., Hao, R., Lai, C. H., Chen, D., et al. (2014). Microtubule acetylation amplifies p38 kinase signalling and anti-inflammatory IL-10 production. Nat. Commun. 5:3479.

Wang, R., Ye, Y., Yang, X., Liu, B., Wang, Z., Chen, S., et al. (2020). SIRT2-dependent HDI deacetylation inhibits colorectal cancer and liver metastases. EMBO Rep. 21:e48183.

Wang, F., Nguyen, M., Qin, F. X., and Tong, Q. (2007). SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell 6, 505–514. doi: 10.1111/j.1474-9726.2007.00304.x

Wang, H., Zhou, W., Zheng, Z., Zhang, P., Tu, B., He, Q., et al. (2012). The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage. DNA Repair 11, 146–156. doi: 10.1016/j.dnarep.2011.10.014

Wang, J., Jiang, J., Chen, H., Wang, L., Guo, H., Yang, L., et al. (2019). FDA-approved drug screen identifies proteasome as a synthetic lethal target in MYC-driven neuroblastoma. Oncogene 38, 6737–6751. doi: 10.1038/s41388-019-0192-5

Wang, R. H., Sengupta, K., Li, C., Kim, H. S., Cao, L., Xiao, C., et al. (2008). Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 14, 312–323. doi: 10.1016/j.ccc.2008.09.001

Wang, W. W., Zeng, Y., Wu, B., Deiters, A., and Liu, W. R. (2016). A chemical biology approach to reveal sirt6-targeted histone H3 sites in nucleosomes. ACS Chem. Biol. 11, 1973–1981. doi: 10.1021/acschembio.6b00243

Wang, X., Waschke, B. C., Woideker, R. A., Chen, S. M. Y., Chen, Z., and Wang, J. H. (2020). HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma. Protein Cell 11, 472–482. doi: 10.1007/s13238-020-00694-x

Wang, Y., He, J., Liao, M., Hu, M., Li, W., Ouyang, H., et al. (2019). An overview of Sirtuins as potential therapeutic target: Structure, function and modulators. Eur. J. Med. Chem. 161, 48–77. doi: 10.1016/j.ejmech.2018.10.028

Wang, Y. P., Zhou, L. S., Zhao, Y. Z., Wang, S. W., Chen, L. L., Liu, L. X., et al. (2014). Regulation of G6PD acetylation by SIRT2 and KAT9 modulates NADPH homeostasis and cell survival during oxidative stress. EMBO J. 33, 1304–1320.

Wang, Z., Zang, C., Cui, K., Schones, D. E., Barski, A., Peng, W., et al. (2009). Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 138, 1019–1031. doi: 10.1016/j.cell.2009.06.049

Watson, P. J., Fairall, L., Santos, G. M., and Schwabe, J. W. (2012). Structure of HDAC3 bound to co-repressor and inositol tetraptahosphate. Nature 481, 335–340. doi: 10.1038/nature10728

Watson, P. J., Millard, C. J., Riley, A. M., Robertson, N. S., Wright, L. C., Godage, H. Y., et al. (2016). Insights into the activation mechanism of class I HDAC complexes by inositol phosphates. Nat. Commun. 7:11262.

Wei, W., Liu, X., Chen, J., Gao, S., Lu, L., Zhang, H., et al. (2017). Class I histone deacetylases are major histone deacetylase: evidence for critical and broad function of histone coacetylase in transcription. Cell Res. 27, 898–915. doi: 10.1038/cr.2017.68

Wei, Z., Song, J., Wang, G., Cui, X., Zheng, J., Tang, Y., et al. (2018). Deacetylation of serine hydroxymethyltransferase 2 by SIRT3 promotes colorectal carcinogenesis. Nat. Commun. 9:4468.

Weinhouse, S. (1956). On respiratory impairment in cancer cells. Science 124, 267–269. doi: 10.1126/science.124.3215.267

Wen, Y. D., Perissi, V., Staszewski, L. M., Yang, W. M., Krones, A., Glass, C. K., et al. (2000). The histone deacetylase-3 complex contains nuclear receptor corepressors. Proc. Natl. Acad. Sci. U.S.A. 97, 7202–7207. doi: 10.1073/pnas.97.13.7202

Weng, C. H., Chen, L. Y., Lin, Y. C., Shih, Y. J., Lin, Y. C., Tseng, R. Y., et al. (2019). Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI. Oncogene 38, 455–468. doi: 10.1038/s41388-018-0454-2

West, A. C., and Johnstone, R. W. (2014). New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest. 124, 30–39. doi: 10.1172/jci69738

Wilson, J. M., Le, V. Q., Zimmerman, C., Marmorstein, R., and Pillus, L. (2006). Nuclear export modulates the cytoplasmic Sir2 homologue Hst2. EMBO Rep. 7, 1247–1251. doi: 10.1038/sj.embor.7400829

Winter, M., Moser, M. A., Meunier, D., Fischer, C., Machat, G., Mattes, K., et al. (2013). Divergent roles of HDAC1 and HDAC2 in the regulation of epidermal
development and tumorigenesis. *EMBO J.* 32, 3176–3191. doi: 10.1038/embj.2013.243

Woods, D. M., Woon, K. V., Cheng, F., Sodre, A. L., Wang, D., Wu, Y., et al. (2017). T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model. *Blood* 130, 146–155. doi: 10.1182/blood-2016-08-731505

Wu, L. P., Wang, X., Li, L., Zhao, Y., Lu, S., Yu, Y., et al. (2008). Histone deacetylase inhibitor desiposipetide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter. *Mol. Cell. Biol.* 28, 3219–3235. doi: 10.1128/mcb.01516-07

Wu, M. Z., Tsai, Y. P., Yang, M. H., Huang, C. H., Chang, S. Y., Chang, C. C., et al. (2011). Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transition. *Mol. Cell.* 43, 811–822. doi: 10.1016/j.molcel.2011.07.012

Xiao, H., Jiao, J., Wang, L., O'brien, S., Newick, K., Wang, L. C., et al. (2016). HDAC5 controls the functions of Foxn3p(T)-regulatory and CD8(+) T cells. *Int. J. Cancer* 138, 2477–2486. doi: 10.1002/ijc.29979

Xu, C., Jin, J., Bian, C., Lam, R., Tian, R., Weist, R., et al. (2012). Sequence-specific recognition of a PaLPxI/L motif by an ankyrin repeat tumbler lock. *Sci. Signal.* 5, ra39. doi: 10.1126/scisignal.2002979

Xu, L., Li, Y., Zhou, L., Dorfman, R. G., Liu, L., Cai, R., et al. (2016). SIRT3 elicits an anti-Warburg effect through HIP1alpha/PDK1/PDHAI1 to inhibit cholangiocarcinoma tumorigenesis. *Cancer Med.* 5, 2380–2391. doi: 10.1002/cam4.2089

Xu, W., Nigo, L., Perez, D., Dokmanovic, M., and Marks, P. A. (2006). Intrinsic apoptotic and thioridoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. *Proc. Natl. Acad. Sci. U.S.A.* 103, 15540–15545. doi: 10.1073/pnas.0607518103

Xu, Y., Zhang, S., Lin, S., Guo, Y., Deng, W., Zhang, Y., et al. (2017). WERAM: a database of writers, readers and historians of histone acetylation and methylation in eukaryotes. *Nucleic Acids Res.* 45, D264–D270.

Yang, W., Liu, S., Xu, J., Zhang, J., Zhang, Y., Chen, X., et al. (2013). Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. *Oncoogene* 32, 599–609. doi: 10.1080/2013.012.81

Yang, W. W., Liang, Y. L., Zhang, Q. X., Wang, D., Lei, M. Z., Qu, J., et al. (2018). Arginine methylation of SIRT7 couples glucose sensing with mitochondria biogenesis. *EMBO Rep.* 19:e46377.

Yang, Y., An, J., Yang, Y., Wu, D., Bai, Y., Cao, W., et al. (2017). Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SP0P-mutated prostate cancer. *EMBO Mol. Med.* 10:e8478.

Yang, L., Ma, X., He, Y., Yuan, C., Chen, Q., Li, G., et al. (2017). Sirtuin 5: a review of structure, known inhibitors and clues for developing new inhibitors. *Sci. China Life Sci.* 60, 249–256. doi: 10.1007/s11427-016-0600-7

Yang, W., Nagasawa, K., Munch, C., Xu, Y., Satterstrom, K., Keong, S., et al. (2016). Mitochondrial sirtuin network reveals dynamic SIRT3-dependent deacetylation in response to membrane depolarization. *Cell* 167, 985–1000.e21.

Yang, W., Xia, Y., Hawke, D., Li, X., Liang, J., Xing, D., et al. (2012). PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. *Cell* 150, 685–696. doi: 10.1016/j.cell.2012.07.018

Yang, W., Xia, Y., Ji, H., Zheng, Y., Liang, J., Huang, W., et al. (2011). Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. *Nature* 480, 118–122. doi: 10.1038/nature10598

Yang, W. M., Inouye, C., Zeng, Y., Bearss, D., and Seto, E. (1996). Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RP3. *Proc. Natl. Acad. Sci.* U.S.A. 93, 12845–12850. doi: 10.1073/pnas.93.23.12845

Yang, W. M., Yao, Y. L., Sun, J. M., Davie, J. R., and Seto, E. (1997). Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. *J. Biol. Chem.* 272, 28001–28007. doi: 10.1074/jbc.272.44.28001

Yang, X., Wang, Z., Li, X., Liu, B., Liu, M., Liu, L., et al. (2018). SHMT2 desuccinylation by SIRT5 drives cancer cell proliferation. *Cancer Res.* 78, 373–386. doi: 10.1158/0008-5472.can-17-1912

Yang, X. J., and Greigore, S. (2005). Class II histone deacetylases: from sequence to function, regulation, and clinical implication. *Mol. Cell. Biol.* 25, 2873–2884. doi: 10.1128/mcb.25.8.2873-2884.2005
Zhao, X., Sternsdorf, T., Bolger, T. A., Evans, R. M., and Yao, T. P. (2005). JMJ2A is a novel N-CoR-interacting protein and is involved in repression of the human transcription factor achaete scute-like homologue 2 (ASCL2/Hash2). *Mol. Cell. Biol.* 25, 6404–6414. doi: 10.1128/mcb.25.15.6404–6414.2005

Zhao, M., Wu, J., Sun, R., Tao, X., Wang, X., Kang, Q., et al. (2019). SIRT5 deficiency suppresses mitochondrial ATP production and promotes AMPK activation in response to energy stress. *PLoS One* 14:e0211796. doi: 10.1371/journal.pone.0211796

Zheng, P., Tu, B., Wang, H., Cao, Z., Tang, M., Zheng, C., et al. (2014). Tumor suppressor p53 cooperates with SIRT6 to regulate gluconeogenesis by promoting FoxO1 nuclear exclusion. *Proc. Natl. Acad. Sci. U.S.A.* 111, 10686–10689. doi: 10.1073/pnas.1411026111

Zhang, P. Y., Li, G., Deng, Z. J., Liu, L. Y., Chen, L., Tang, J. Z., et al. (2016). Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. *Nucleic Acids Res.* 44, 3629–3642. doi: 10.1093/nar/gkv1504

Zhang, X., Chen, X., Lin, J., Lwin, T., Wright, G., Moscinski, L. C., et al. (2012a). Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. *Oncogene* 31, 3002–3008. doi: 10.1038/onc.2011.470

Zhang, X., Zhao, X., Fiskus, W., Lin, J., Lwin, T., Rao, R., et al. (2012b). Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. *Cancer Cell* 22, 506–523. doi: 10.1016/j.ccc.2012.09.003

Zhang, Y., Kwon, S., Yamaguchi, T., Cubizolles, F., Rousseaux, S., Kneissel, M., et al. (2008). Dicer interacts with SIRT7 and regulates H3K18 deacetylation in response to DNA damaging agents. *Nucleic Acids Res.* 44, 3629–3642. doi: 10.1093/nar/gkv1504

Zhu, G., Tao, T., Zhang, D., Liu, X., Qiu, H., Han, L., et al. (2016). O-GlcNAcylation of histone deacetylases 1 in hepatocellular carcinoma promotes cancer progression. *Glycobiology* 26, 820–833. doi: 10.1093/glycob/cww025

Zhu, W. G. (2017). Regulation of p53 acetylation. *Sci. China Life Sci.* 60, 321–323. doi: 10.1007/s11427-016-0353-0

Zhao, Y., Yang, J., Liao, W., Liu, X., Zhang, H., Wang, S., et al. (2010). Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity. *Nat. Cell Biol.* 12, 665–675. doi: 10.1038/ncb2069

Zhou, L., D’urso, A., Toiber, D., Sebastian, C., Henry, R. E., Vadysirisack, D. D., et al. (2010). The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. *Cell* 140, 280–293. doi: 10.1016/j.cell.2009.12.041

Zhou, L., Wang, F., Sun, R., Chen, X., Zhang, M., Xu, Q., et al. (2016). SIRT5 promotes IDH2 desuccinylation and G6PD deglutarylation to enhance cellular antioxidant defense. *EMBO Rep.* 17, 811–822. doi: 10.15252/embr.201541643

Zhu, X., Marks, P. A., Rifkind, R. A., and Richon, V. M. (2001). Cloning and characterization of a histone deacetylase, HDAC9. *Proc. Natl. Acad. Sci. U.S.A.* 98, 10572–10577. doi: 10.1073/pnas.191375098

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Li, Tian and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.